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GENERAL INTRODUCTION 
 
 
Chapter 1 
Ovarian cancer 
Ovarian cancer is the fourth most common cause of cancer deaths among females in the 
western world after cancer of the breast, large bowel and lung. The yearly incidence of 
ovarian cancer is approximately 23,100 cases in the United States1  and 1,400 cases in 
the Netherlands.2 The disease accounts for approximately 14,000 and 1,000 cancer 
related deaths per year, respectively. Because of the high fatality rate and the late stage 
at which the disease normally starts to cause complaints, ovarian cancer is nicknamed 
‘the silent lady killer’. 
The majority of ovarian cancers (90 %) originate from the epithelial layer of the ovary. 
Non-epithelial ovarian cancers represent a separate class of ovarian malignancies and 
are beyond the scope of this thesis. The etiology of ovarian cancer remains largely 
unknown. A genetic component is present in 5-10 % of the cases.3 Well-known examples 
are the hereditary BRCA1 and BRCA2 gene mutations. BRCA1 and BRCA2 carriers have 
an enhanced life-time risk for developing ovarian carcinoma of approximately 50 % and 
15-20 %, respectively.4,5 In non-hereditary ovarian cancer, an inverse correlation between 
the incidence of ovarian cancer with the number of ovulations was found. A protective 
effect of the use of oral contraceptives was consistently found in various studies.6,7 These 
observations support an old theory that entrapment of epithelial cells in the ovarian 
stroma after an ovulation contributes to the development of ovarian cancer (incessant 
ovulation theory).8                    
The poor prognosis of epithelial ovarian cancer is mainly caused by its clinical behaviour. 
In the early stage of the disease, when the malignant cells are still confined to the 
ovaries, surgical resection of one or both ovaries can provide a cure. Unfortunately, 
diagnosis of these stages often is a matter of coincidence as symptoms are normally 
absent or vague. Further tumor growth can be distinguished in (1) release of malignant 
cells from the epithelial surface resulting in ascitic tumor cells and serosal implants; (2) 
direct extension to surrounding structures in the pelvis; (3) distant lymphogenic spread to 
pelvic and para-aortic lymph nodes9; (4) hematogenous and further lymphatic 
dissemination beyond the abdomen. Dissemination beyond the abdomen is uncommon, 
even in the presence of massive ascites.  
Primary prevention has become possible for patients with a known BRCA1 or BRCA2 gene 
mutation. Medical, ethical and social aspects should be considered when deciding 
whether to proceed to prophylactic resection of the ovaries and fallopian tubes. Current 
diagnostic tests that can be used for the secondary prevention of ovarian carcinoma in 
the general female population do not to meet the criteria for population screening.10 A 
large trial is ongoing to determine if tumor marker CA125 in combination with intravaginal 
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ultrasonography is a diagnostic combination that meets essential screening 
requirements.11 
Over the past 25 years the principal treatment of advanced ovarian cancer has been 
radical debulking surgery followed by chemotherapy. At the moment, paclitaxel combined 
with cisplatin or carboplatin is the standard first-line treatment in most countries12, 
resulting in response rates of 70 to 80%. In comparison with former regimens, response 
rates have ameliorated and tolerability has improved. However, only small improvements 
in overall survival have been achieved. 
The inability to control the disease within the peritoneal cavity is a major cause of 
treatment failure in patients with ovarian cancer. Further progress will depend on new 
treatments that can eradicate residual disease after surgery and chemotherapy. The use 
of radiolabeled antibodies to achieve this goal has been investigated in the past decades. 
Following intravenous or intraperitoneal administration, radiolabeled antibodies against 
ovarian cancer associated antigens are capable to bind specifically to their target on the 
tumor cell membrane. More recently, radiolabeled peptides have been introduced to 
achieve this same goal. Therapies using radiolabeled antibodies (radioimmunotherapy (RIT)) 
and radiolabeled peptides (peptide receptor radionuclide therapy (PRRT)) are promising 
candidates for adjuvant, radionuclide based therapy for ovarian carcinoma. 
 
 
Radionuclides for radioimmunotherapy 
For RIT purposes, β-emitting radionuclides are most frequently. The characteristics of β-
emitting radionuclides currently used for RIT are summarized in table 1. 131I has a long 
tradition in the treatment of thyroid carcinoma. It was the first radionuclide routinely applied 
in RIT. 131I can be linked stably to immunoglobulins using relatively simple labeling 
technology. In addition to its medium energy β-particle, 131I emits high energy 364 keV 
photons allowing imaging, but also requiring strict radiation safety measures. In the past 
decade several new β-emitters have become available and have been proposed for RIT. 90Y 
emits high energy β-particles (Emax = 2.28 MeV), and due to the absence of γ-emissions it 
requires less safety precautions. The lack of γ-emissions prevents combined RIT and 
radioimmunoscintigraphy. Therefore, 111In is used as a surrogate for 90Y when scintigraphy 
is required. 186Re, 188Re as well as 177Lu all have medium energy β-emission with a low 
abundance γ-emission that can be used for imaging. 
Theoretically, low energy β-emitters are more advantageous for the treatment of small-sized 
peritoneal carcinomatosis as often present in ovarian carcinoma: the penetration range of 
their β-emissions is better suited to kill single cells and small clusters of cells. β-emitters 
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with higher energies are considered more suitable for the treatment of larger tumor 
deposits. 
To label immunoglobulins or peptides with 90Y, chelators such as DOTA and their derivatives 
are most commonly used. Their high in vivo stability reduces release of the radionuclide and 
subsequent incorporation of 90Y into the mineral bone. As a result the radiation dose to the 
red marrow, being the dose limiting organ in RIT, is minimized. The labeling technology for 
90Y, 177Lu and 67Cu is similar, if not identical. 
 
 
 half-life 
(time) 
βmax 
(keV) 
γ 
(keV) 
% of γ 
(%) 
Pros 
 
Cons 
 
67Cu 62 days 390 184  49  limited availability 
177Lu 6.7 days 497 208  11 
attractive overall 
characteristics 
 
131I 8 days 606 364  81 good availability 
excessive γ, 
low labeling efficiency 
186Re 90 h 1080 137  9 
excellent 
γ-imaging 
laborious labeling 
technology 
188Re 17 h 2110 155  15 
generator 
produced 
laborious labeling, 
short half-life 
90Y 64 h 2280 - - high energy β absence of γ 
 
Table 1. Characteristics of the most commonly used β-emitting radionuclides applied in 
radioimmunotherapy. 
 
 
Radioimmunotherapy in ovarian cancer 
In the past two decades, significant preclinical as well as clinical experience using 
radiolabeled monoclonal antibodies has been acquired in the treatment of ovarian 
carcinoma. Radiolabeled antibodies directed against tumor associated antigens have 
been shown to preferentially localize in ovarian carcinoma tumors. This observation can 
be exploited to image tumors scintigraphically. The ability of anti-tumor antibodies to 
preferentially accumulate in tumors formed the basis to investigate the use of 
monoclonal antibodies for therapeutic use. RIT has been tested against a wide variety of 
human malignancies. It proved to be an effective approach for the treatment of 
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hematological malignancies that are relatively radiosensitive.13 Complete and durable 
responses in patients with  B-cell lymphomas have been achieved.14 
Initial RIT studies in patients with solid tumors have shown the limitations of this 
approach. Several physiological factors limit the uptake and penetration of antibodies in 
tumors. Poor vascularisation, heterogeneous antigen expression and an elevated 
interstitial pressure in combination with relatively long transport distances in the 
interstitium limit the uptake and impede the penetration of antibodies into tumors.15 
Therefore, RIT is considered less suitable (if not unsuited) for the treatment of large solid 
tumor masses. 
More recently, several studies have shown that radioimmunotherapy applied under more 
restricted conditions (therapy at MTD, small volume disease, locoregional administration) 
can lead to significant responses in patients with solid tumors like colorectal carcinomas, 
medullary thyroid carcinoma, ovarian carcinoma and breast carcinoma. Complete 
responses, however, have not been reported yet, most likely due to the relatively large 
size of the tumors in most studies. Presumably minimal residual disease is the ideal target 
for this treatment modality. 
Intraperitoneally administered 177Lu-CC49 was well tolerated by patients with ovarian 
carcinoma who failed remission after surgery and chemotherapy. However, 6 of 8 
patients with gross disease progressed.16 Epenetos et al. evaluated the long-term survival 
of patients treated with intraperitoneal RIT, using HMFG1 labeled with 90Y following 
cytoreductive surgery and platinum-based chemotherapy.17 They found that a substantial 
proportion of patients who achieved a complete remission with conventional therapy can 
achieve a long-term survival (78% more than 10 years) when treated with adjuvant 
intraperitoneal RIT. 
The theoretically favourable route of administration for RIT in ovarian carcinoma patients 
was analyzed: no clear preference was found after simultaneous injection of radiolabeled 
cMov18 intravenously and intraperitoneally in 15 patients with suspected or recurrent 
ovarian carcinoma.18 
 
 
 The αvβ3 integrin for targeted delivery of anti-tumor therapies 
Integrins are a family of transmembrane glycoproteins, that function in cellular adhesion, 
migration and signal transduction. The term integrin was derived from the ability of these 
proteins to link the extracellular matrix proteins with the intracellular cytoskeleton.19 Each 
member of this family consists of two non-covalently bound polypeptides (α and β), both 
of which traverse the cell membrane. To date, 17 α-subunits and 8 β-subunits have been 
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identified, which associate selectively to form at least 23 integrins. Integrins can bind 
extracellular matrix proteins or cell surface ligands through short peptide sequences. 
Combinations of different integrins on cell surfaces allow cells to recognize and respond 
to a variety of different extracellular matrix proteins.20 Integrin-mediated cell adhesion 
may affect the cell cycle kinetics, or may cause anchorage-dependent cell death or 
anoikis.21,22  
The α subunit αv can associate with various integrin β subunits. At present there are at 
least three distinct β subunits that associate with αv, namely, β1, β3, and β5. The integrin 
αvβ3, also referred to as the vitronectin receptor, binds to a variety of extracellular matrix 
proteins, including vitronectin, fibrinogen, laminin, collagen, von Willebrand Factor and 
osteopontin through their exposed Arginine-Glycine-Aspartic acid (RGD) amino acid 
sequence.23 It is expressed on a variety of cell types, including osteoclasts, vascular 
smooth muscle cells, endothelial cells and various tumor cells. αvβ3 is minimally 
expressed on normal quiescent endothelial cells, but significantly up-regulated on 
proliferating endothelium.24 The proliferation of new blood vessels from pre-existing 
capillairies (angiogenesis) is a rare process in adult human beings. Apart from the 
menstrual cycle, abundant angiogenesis is a characteristic feature during various 
pathologic processes, i.e. wound healing, macular degeneration and diabetic retinopathy, 
psoriasis, endometriosis and rheumatoid arthritis.25 More importantly, angiogenesis is a 
characteristic and essential feature of the growth of solid tumors. In any tumor that grows 
beyond the size of 1-2 mm in diameter, the formation of new vessels is required. Recent 
studies have shown that this not only applies for solid tumors but even for hematological 
malignancies (i.e., lymphoma and leukemia).26-28 Since it has been recognized that the 
growth of virtually all tumors is dependent on angiogenesis, the process of angiogenesis 
has been suggested as a target for tumor therapy. αvβ3 is one of the few identified 
candidates that could serve as a chemical structure to target newly formed blood vessels. 
Several vehicles have been developed to target tumor vasculature via αvβ3. It was found 
that peptides and antibodies that specifically bind αvβ3 induced endothelial cell 
apoptosis, indicating that this integrin plays a vital role in endothelial cell survival during 
angiogenesis.29 The most widely used vehicle for targeting the αvβ3 integrin is the 
monoclonal antibody LM609. Intravenous injection of this antibody inhibited the growth 
of human breast cancer xenografts in SCID mice.30 The LM609 antibody has now been 
humanized. A phase I study in patients with progressive tumors (stage IV) with humanized 
LM609 (Vitaxin®) was completed.31 Treatment consisted of six weekly infusions of Vitaxin 
(0.1 - 4.0 mg/kg/week). Out of 17 patients treated, 14 were evaluable for response. The 
treatment was well tolerated with little or no toxicity. One patient had a partial response, 
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and seven patients demonstrated stable disease. Further study to determine the 
therapeutic effect of Vitaxin (2 mg/kg/week) was initiated. 
Immunohistochemical studies with LM609 have shown that apart from the expression on 
proliferating endothelial cells, the αvβ3 integrin is also expressed on various types of 
tumor cells such as ovarian carcinoma cells and melanoma cells. A correlation between 
the expression of the αvβ3  integrin and the prognosis of cancer patients was found in 
breast cancer.32 A high expression of αvβ3 was found in advanced stages of 
neuroblastoma33 and in highly differentiated ovarian carcinoma.34 These studies 
indicated that RGD-peptides could potentially target various tumor types. RGD-peptides 
did not induce apoptosis in αvβ3 expressing melanoma cells. However, when 
administered to nude mice the growth of melanoma xenografts was inhibited. Histological 
examination of the tumors indicated that this effect was primarily due to inhibition of 
angiogenesis.35 These studies indicate that RGD-peptides can interact with αvβ3 both on 
tumor cells and on proliferating endothelial cells. 
In summary, αvβ3 integrin is selectively expressed on sprouting endothelium in growing 
tumors and on various types of cancer cells and thus αvβ3 could be a suitable target for 
tumor targeting agents. Theoretically, radiolabeled RGD-peptides could be used to 
scintigraphically visualize tumors and to determine their αvβ3 expression status. In 
addition, while labeled with β-emitters, they potentially can eridicate tumors by targeting 
and irradiating αvβ3 expressing tumor cells and proliferating endothelial cells.   
 
 
Peptide receptor radionuclide targeting 
During the past decade radiolabeled receptor binding peptides have emerged as an 
important class of radiopharmaceuticals for tumor diagnosis and therapy. The specific 
receptor binding property of the ligand can be exploited by labeling the ligand with a 
radionuclide and using the radiolabeled ligand as a vehicle to guide the radioactivity to 
the tissues expressing a particular receptor. Theoretically, the high affinity of the ligand 
for the receptor facilitates retention of the radiolabeled ligand in receptor-expressing 
tissues, while its relatively small size (e.g. as compared to antibodies) facilitates rapid 
clearance from the blood and other nontarget tissues. The concept of using radiolabeled 
receptor binding peptides to target receptor-expressing tissues in vivo has stimulated a 
large body of research in nuclear medicine. Receptor binding peptides labeled with 
gamma emitters (123I, 111In, 99mTc) could facilitate the visualization of receptor-expressing 
tissues noninvasively: a technique referred to as peptide-receptor radionuclide imaging 
(PRRI). In addition, labeled with β-emitters (131I, 90Y, 188Re, 177Lu) these peptides have the 
 15 
 
Chapter 1 
potential to eradicate receptor-expressing tissues: an approach referred to as peptide-
receptor radionuclide therapy (PRRT).  
The concept of targeting receptor expressing cells in vivo with their radiolabeled ligands 
has already proven its validity. For example, it has been shown that various tumors 
expressing somatostatin receptors can be targeted very effectively with somatostatin 
analogs. Somatostatin (SST) receptors are expressed in the majority of neuro-endocrine 
tumors. The 8-aminoacid analog, octreotide, has a high affinity for the somatostatin 
receptor subtypes 2 and 5 (SSTR2 and SSTR5). Octreotide labeled with 111In via DTPA can 
be used to scintigraphically visualize tumor lesions of neuroendocrine origin (i.e. pituitary 
tumors, insulinoma, endocrine pancreatic tumors, SCLC, carcinoids, neuroblastomas). In 
patients with gastroenteropancreatic tumors the sensitivity of 111In-DTPA-octreotide 
scintigraphy was between 80 and 90%.36-38 A new somatostatin analog, DOTA-Tyr3-
octreotide, that can be stably labeled with 90Y, has now been developed for radionuclide 
therapy studies. Studies to determine the therapeutic efficacy of 90Y-DOTA-Tyr3-octreotide in 
cancer patients are currently ongoing at various institutions. First results of a study in 
patients with advanced SST receptor-positive tumors showed that treatments with 90Y-DOTA-
Tyr3-octreotide caused stabilization of disease in 20 of the 29 patients and a partial 
remission in two patients.39 
 
 
Radionuclide targeting of αvβ3 
Radiolabeled RGD-peptides could preferentially guide radionuclides to growing tumors by 
binding the αvβ3 integrin or the so-called vitronectin receptor as expressed on proliferating 
endothelial cells in the tumor and/or on the tumor cells themselves. Labeled with γ-emitters 
(111In, 99mTc) these peptides could be used as tracers to noninvasively visualize and quantify 
αvβ3 expression in tumors. Such a tracer potentially could detect tumors expressing αvβ3 
and tumors with αvβ3-dependent angiogenesis. This tracer could be used to select those 
patients that would be most amenable to anti-angiogenetic therapy with radiolabeled RGD-
peptides. 
A few groups have tested RGD sequence containing peptides for their ability to bind the αvβ3 
integrin. It was found that the cyclic derivative cyclic(Arg-Gly-Asp-D-Phe-Val) was a 100-fold 
better inhibitor of cell adhesion to vitronectin when compared to the linear variant, with an 
IC50 value in the lower nanomolar range.40,41 It was shown that besides the essential RGD 
sequence, a hydrophobic amino acid in position 4 increases the affinity for αvβ3.42 Based on 
this finding, Haubner et al. designed five peptides that could be radioiodinated by 
introducing a tyrosine residue. Two of these peptides, cyclic(Arg-Gly-Asp-D-Tyr-Val) and 
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cyclic(Arg-Gly-Asp-D-Phe-Tyr) (designated as P1 and P4, respectively) were studied in vivo.43 
The IC50 of the inhibition of binding of vitronectin of these peptides was 2 nmol/l. The 
biodistribution of the radioiodinated peptides was studied in nude mice with various tumors 
(M21 melanoma, MaCaF mammary carcinoma, and osteosarcoma). The peptides rapidly 
cleared from the blood; blood levels were lower than 1% ID/g as early as 10 min p.i. Tumor 
uptake peaked at 10 min postinjection (3.50 %ID/g) and decreased to 0.92 %ID/g at 4 h p.i. 
Due to the rapid blood clearance of the peptides, tumor/blood ratios reached values 
between 6.8 and 8.0 at 4 h p.i. Both peptides mainly cleared via the hepatobiliairy route, 
and revealed relatively high hepatic uptake especially at early time points (10 %ID/g, 1 h 
p.i.). Subsequently, a glycosylated version of P2 was synthesized in an attempt to produce a 
more hydrophilic compound that would clear predominantly via the kidneys.44 This 
compound, designated GP2 (cyclic(Arg-Gly-Asp-D-Tyr-Lys[SAA])) had a somewhat higher IC50 
(40 nmol/l) for inhibiting  vitronectin binding. GP2 was radioiodinated and tested in the 
same mouse tumor models. The glycosylated peptide showed a longer circulatory half-life 
and a significantly reduced uptake in the liver (2 vs. to 10 %ID/g at 1 h p.i.). Most 
importantly, the glycosylated RGD-peptide had a clearly enhanced uptake in the tumor (3.0 
%ID/g vs. 0.92 %ID/g at 4 h p.i.). 
The nonglycosylated version of this peptide cyclic(Arg-Gly-Asp-D-Tyr-Lys) was conjugated with 
DTPA. In vitro studies showed that the peptide was internalized by Bon cells expressing αvβ3  
integrin.  The tumor targeting potential of this peptide labeled with 111In was tested in rats 
with s.c. autologous pancreatic CA20948 tumors. This study showed that the introduction of 
the DTPA moiety in the peptide (via the ε-aminogroup of the lysine residue) made the 
peptide hydrophilic and facilitated renal clearance, while the non-DTPA conjugated peptide 
predominantly cleared via the liver.45 Uptake in the CA20948 pancreatic tumors amounted 
to 0.2 %ID/g (24 h p.i.), while the peptide cleared almost completely from the blood (0.003 
%ID/g, 24 h p.i.). Twenty-four hours after injection of the 111In-labeled DTPA-RGD analogue, 
the tumor was the tissue with the highest concentration of radioactivity, with the exception 
of the kidneys (0.5 %ID/g). 
Untill now, there has been one report on the use of αvβ3 integrin targeting peptides for 
scintigraphic imaging of tumors in patients. Sivolapenko et al. synthesized a linear 
decapeptide designated αP2 containing two RGD sequences. The αP2 peptide was 
radiolabeled with 99mTc via the cysteine residue in the peptide. Fourteen melanoma 
patients received 185-1110 MBq of the labeled peptide i.v. and were imaged up to 3 h 
p.i. The peptide cleared rapidly from the blood (t½α = 6 min and t½β = 35 min) and from 
the body (1 h p.i. >90 %ID in kidneys and bladder). Sixteen out of the 22 metastatic 
lesions in these patients were visualized.46 
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Outline of this thesis 
RIT and PRRT are potential strategies for the treatment of solid tumors. Although responses 
have been documented in patients with several tumor types, both treatments still have their 
limitations. New possibilities for both RIT as well as PRRT were evaluated in 5 preclinical 
studies that are described in this thesis. These studies adressed the following questions:  
 
What is the most optimal radionuclide for HMFG1-based, intraperitoneal RIT ?  
Recently, promising β-emitting radionuclides became available that could improve 
therapeutic results of intraperitoneally administered RIT for ovarian cancer. Two of these 
new radionuclides (90Y, 186Re)  were compared with the more established radionuclide 131I 
when labeled to the antibody HMFG1 (chapter 2). 
 
Is radiolabeled RGD-peptide DOTA-E-(RGDfK)2 suitable for PRRI and PRRT in subcutaneous, 
ovarian carcinoma  xenografts ? 
Biodistribution, imaging and therapy studies were performed with  an 111In and 90Y-labeled  
dimeric RGD-peptide in nude mice bearing OVCAR-3 ovarian carcinoma xenografts (chapter 
3). 
 
Can the radiation dose of 90Y-labeled RGD-peptide be predicted using 111In-labeled RGD-
peptide as a surrogate? 
In healthy dogs, doses to relevant organs were calculated after injection of 86Y- DOTA-E-
(RGDfK)2 (PET-camera imaging) and after injection of 111In-DOTA-E-(RGDfK)2 (dynamic 
gamma-camera imaging). It was studied whether the organ doses by these two approaches 
were similar. This would mean that the more simple gamma-camera imaging can be used 
for adequate estimation of radiation doses during PRRT (chapter 4).   
 
Can tumor uptake be improved using a dimeric RGD-peptide instead of a monomeric RGD-
peptide ? 
Tumor uptake of the monomeric 99mTc-HYNIC-(RGDfK) and the dimeric 99mTc-HYNIC-E-
(RGDfK)2 were compared in the OVCAR-3 ovarian carcinoma xenograft mouse model 
(chapter 5). 
 
Can rapid dose fractionation further improve tumor uptake and therapy results of 111In- 
DOTA-E-(RGDfK)2 and 90Y- DOTA-E-(RGDfK)2, respectively ? 
In the OVCAR-3 ovarian carcinoma mouse model, the biodistribution after one injection of 
111In-DOTA-E-(RGDfK)2 was compared to that of 5 successive injection with a 5-fold reduced 
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peptide dose. In addition, PRRT using single and fractionated doses were compared 
(chapter 6). 
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Chapter 2 
Abstract 
 
Despite debulking surgery and multidrug chemotherapy, advanced stage ovarian cancer 
has a high mortality rate. Radioimmunotherapy (RIT) is a treatment modality using 
specific, radiolabeled antibodies that guide cytotoxic radionuclides to cancer cells. In the 
present study, the therapeutic efficacy of RIT with murine monoclonal antibody HMFG1 
labeled with three different β radiation emitting radionuclides (90Yttrium, 186Rhenium and 
131Iodine) was assessed in athymic BALB/c mice with intraperitoneally (i.p.) growing 
NIH:OVCAR-3 ovarian carcinoma xenografts. Each of the three (i.p.) administered 
radiolabeled antibody preparations (90Y-HMFG1, 186Re-HMFG1 and 131I-HMFG1) caused a 
significant delay in ascites formation and mortality as compared to the control groups 
treated with 90Y-labeled irrelevant antibody, nonradiolabeled HMFG1 or phosphate 
buffered saline. I.p. administered 90Y-HMFG1 was shown to have a significantly higher 
abdominal retention as compared to the i.p. administered irrelevant antibody 90Y-G250. 
Furthermore, i.p. administered 90Y-HMFG1 more effectively inhibited tumor growth than 
intravenously (i.v.) administered 90Y-HMFG1. It was concluded that in i.p. located 
malignant disease with ascitic cell clusters and tumor deposits, i.p. administration of RIT 
seemed preferable as compared to i.v. administration. The choice of the most optimal 
radionuclide in i.p. located malignancies needs further research, but could well depend 
on tumor characteristics such as the size of the tumor lesions. 
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Introduction 
 
Ovarian cancer was the primary cause of death in 928 women in the Netherlands in 
1999 and accounted for 5.2% of all cancer deaths among women and for 54% of all 
deaths from gynecological cancer.1 Although most advanced stage patients reach 
complete clinical remission after initial surgical and chemotherapeutic treatment, the 
disease relapses in the majority of patients. In most cases, ovarian cancer is confined to 
the peritoneal cavity, and therefore the intraperitoneal (i.p.) route of administration of 
therapeutics seems attractive. Radioimmunotherapy (RIT) uses antibodies with specific 
affinity for tumor-associated antigens on cancer cells, labeled with cytotoxic radionuclides 
to treat cancer.2 I.p. RIT using the 90Y-radiolabeled antibody HMFG1 has been studied in 
an adjuvant setting for the treatment of ovarian cancer patients3,4, and currently this 
approach is the subject of a multicenter phase III trial. The murine monoclonal antibody 
HMFG1 binds to a repetitive aminoacid sequence (PDTR) in the peptide core of the MUC1 
glycoprotein.5 In contrast to MUC1 expressed by nontumor cells, MUC1 expressed on 
tumor cells has aberrantly glycosylated carbohydrate sidechains and as a result tumor 
cells expose more HMFG1 epitopes.6 This epitope is expressed on most human 
adenocarcinomas, including more than 90% of the epithelial ovarian cancers.7 
Various radionuclides have been proposed for use in RIT. β radiation emitters such as 
131I, 90Y and 186Re are most frequently used because of their potent cytotoxic effect, their 
suitable half-life and their availability. However, these three β emitters vary substantially 
in terms of physical half-life as well as in the energy of their β emissions: 90Y (βmax 2.3 
MeV, t½ 64 h), 186Re (βmax 1.1 MeV, t½ 91 h) and 131I (βmax 0.6 MeV, t½ 192 h). Most 
importantly, as a result the maximum penetration range of the radiation in tissue of 90Y, 
186Re and 131I is 12, 5 and 2 mm, respectively. Comparative studies could reveal which 
radionuclide has the most optimal characteristics for the treatment of malignant disease. 
Here we used a mouse model of ovarian cancer to study the therapeutic potential of 
HMFG1 monoclonal antibody labeled with the β emitting radionuclides 131I, 90Y and 186Re. 
 
 
Materials and methods 
 
Monoclonal antibodies 
HMFG1 (a kind gift of Antisoma plc, London, UK) is a murine monoclonal IgG1 antibody 
directed against the PDTR epitope of the MUC1 glycoprotein.5,6 Immunohistochemical 
studies have shown that the epitope is expressed on more than 90% of the ovarian 
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carcinomas.7 MUC1 is expressed on the apical side of most glandular epithelia.8 
Radiolabeled HMFG1 localized specifically in the mucosa of the upper respiratory tract 
when injected intravenously (i.v.) in patients.9 G250 is a murine monoclonal IgG1 
antibody directed against the G250 antigen expressed on renal cell carcinoma cells10, 
but not on ovarian carcinoma cells. 
 
Radiolabeling of the antibodies 
111In-DTPA-HMFG1 and 90Y-DTPA-HMFG1 
The bifunctional chelating agent isothiocyanatobenzyl-diethylenetriaminepentaacetic acid 
(ITC-DTPA) was conjugated to the antibody as described previously.11 HMFG1-DTPA was 
labeled with 111In (Mallinckrodt, Petten, the Netherlands) in acetate buffer, pH 5.5 (37 
MBq/mg, 20 min at room temperature). Radiochemical purity was checked by instant 
thin layer chromatography (ITLC) using silicagel strips (Gelman Sciences, AnnArbor, MI, 
USA) with 0.15 M citrate buffer, pH 6 as the mobile phase. Labeling efficiency exceeded 
95%. Analogously DTPA-HMFG1 was radiolabeled with 90Y (NEN, Boston, MA, USA) 
revealing 90Y-DTPA-HMFG1 with a specific activity of 200 MBq/mg. The immunoreactive 
fraction of radiolabeled HMFG1 preparations as determined  on OVCAR-3 cells12 
exceeded 60%. 
 
111In-DTPA-G250 and 90Y-DTPA-G250 
G250 was conjugated with ITC-DTPA as described above. 111In (37 MBq) or 90Y (370 
MBq) was added to 1 mg DTPA-G250 in acetate buffer, pH 5.5. After incubation for 20 
minutes ITLC indicated that the labeling efficacy was higher than 95%. The 
immunoreactive fraction of both preparations as determined on SK-RC52 renal  
carcinoma cells was 63%. 
 
186Re-MAG3-HMFG1 
HMFG1 was labeled with 186Re using the MAG3 chelator as described previously.13 
Briefly, 180 µg S-benzoyl-MAG3 was labeled with 925 MBq 186Re (10 min, 100 °C). 
Following derivatization of the 186Re-MAG3 with 2,3,5,6-tetrafluorphenol (TFP), the 186Re-
MAG3-TFP was purified on a Sep-Pak C18 cartridge (Waters, Milford, MA, USA) and 
subsequently reacted with 3.6 mg HMFG1. The conjugated 186Re-MAG3-HMFG1 was then 
purified on a PD-10 column (Amersham Pharmacia, Woerden, the Netherlands). 
Radiochemical purity of the 186Re-MAG3-HMFG1 exceeded 95%. Specific activity was 110 
MBq/mg. 
 26
Intraperitoneal radioimmunotherapy in ovarian cancer 
131I-HMFG1 
HMFG1 was radioiodinated according to the IodoGen method14 and purified by 
gelfiltration on a PD-10 column (Amersham Pharmacia). Specific activity of the 131I-
HMFG1 was 250 MBq/mg. 
 
Maximum tolerated dose 
To determine the maximum tolerated dose (MTD) of each radiolabeled antibody 
preparation, escalating doses of each radiolabeled radionuclide were injected in 7-8 
weeks old, female nude BALB/c mice (body-weight:18-22 g) without tumor. The starting 
dose was 4.4, 3.0, 7.4 and 14.8 MBq for 90Y-HMFG1 (i.p.), 90Y-HMFG1 (i.v.), 131I-HMFG1 
(i.p.) and 186Re-HMFG1 (i.p.), respectively. Activity doses were increased with steps of 15-
20% for each radionuclide. Three to 5 mice were used per dose level. The MTD was 
defined as the dose level below the lowest dose level that caused death or loss of more 
than 20% of initial total body weight. Fifty-µl blood samples were taken by retro-orbital 
puncture once a week to monitor blood hematology (hemoglobin, leucocytes and 
platelets). Samples were analyzed using a fully automated hematological analyser (Bayer, 
Mijdrecht, the Netherlands). In addition, body weight and survival were monitored twice a 
week. 
 
Nude mouse tumor model 
To ensure a reproducible growth of the tumors in the mice, NIH:OVCAR-3 ovarian 
carcinoma cells were serially transplanted i.p. in female BALB/c nude mice. On day 0 
OVCAR-3 cells were harvested from a mouse with ascitic tumor, and  20 mice were 
inoculated i.p. with 1.107 OVCAR-3 cells. As shown in figure 1, OVCAR-3 cells in the 
peritoneal cavity proliferated exponentially, with a doubling time of approximately 6 days. 
The radiolabeled antibody preparations were administered 9 days after tumor inoculation 
when approximately 15.107 cells were present in the peritoneal cavity. At this stage 
numerous solid tumor depositions were observed on the omentum, mimicking the 
‘omental cake’ phenomenon as observed in ovarian cancer patients. The rest of the 
abdomen did not show any macroscopic evidence of tumor growth. The ascitic fluid was 
macroscopically turbid and contained clusters of OVCAR-3 tumor cells. The studies in 
mice with i.p. OVCAR-3 tumors were approved by the local experimental animal 
committee. 
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Figure 1. Total number OVCAR-3 cells harvested from the intraperitoneal cavity after i.p. 
injection of 1.107 OVCAR-3 ovarian carcinoma cells in female athymic BALB/c mice on 
day zero (3 mice per time point; mean ± SD). 
 
 
Biodistribution study 
The biodistribution of i.p. injected specific and nonspecific radiolabeled antibody was 
studied in mice. 111In-HMFG1 (0.37 MBq) or 111In-G250 was injected i.p. in mice with i.p. 
growing OVCAR-3 tumors 9 days after tumor inoculation. At four time points postinjection 
(p.i.) (4, 24, 72 and 168 h) the biodistribution of the radiolabeled antibodies was 
determined (5 mice/group). OVCAR-3 cells were harvested by rinsing the abdominal 
cavity twice with 5 ml 0.9% NaCl. Cells were spun down (1000 rpm, 5 min), and the 
activity in cell pellet and the supernatant was determined in a shielded well-type gamma 
counter (1480 Wizard, Wallac Oy, Turku, Finland). In addition, before the animals were 
killed, scintigraphic images were acquired on a gamma camera (Siemens Inc, Hoffman 
Estates, IL, USA) using a medium energy collimator.  
 
Survival study 
Seven groups of 10 female BALB/c nude mice received the radiolabeled antibody 
preparations at MTD i.p. or i.v. Twice a week after administration total body weight was 
recorded. When macroscopic ascites developed or body-weight exceeded 30 g, mice were 
killed by CO2 suffocation. 
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Statistical considerations 
Differences in tissue uptake of the radiolabeled antibodies were compared using the 
Mann-Whitney test. The level of significance was set at P<0.05 and Bonferroni correction 
for multiple testing was applied. Differences in survival between treatment groups were 
compared using a logrank test for survival analysis. The level of significance was set at 
P<0.05 and Bonferroni correction for multiple testing was applied. 
 
 
Results 
 
Maximum tolerated dose 
The MTD of the radiolabeled antibody preparations in athymice mice are shown in table 
1. Analysis of the peripheral blood showed a transient decrease in hemoglobin, leucocyte 
counts, and platelet counts, indicating that the radiolabeled antibodies induced transient 
bone marrow suppression. A typical example is shown in figure 2. Decrease of all three 
parameters was dose-dependent with each of the radiolabeled preparations. 
 
 
Group Therapeutic MTD dose (MBq) 
1 90Y-HMFG1 ip 6.3  
2 90Y-HMFG1 iv 4.6 
3 90Y-G250 ip 6.3 
4 186Re-HMFG1 ip 11.8 
5 131I-HMFG1 ip 20.3 
6 HMFG1 n.a. 
7 PBS n.a. 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Antibody preparations and corresponding MTD doses that were administered to 
the experimental groups in the RIT experiment (n.a. = not applicable). 
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Figure 2. Peripheral blood parameters in 8 weeks old, healthy female athymic BALB/c 
mice after injection of 6.3 MBq 90Y-HMFG1 i.p. Results at day 0 were set at baseline. 
 
 
Biodistribution study 
The results of the comparative biodistribution study of the specific antibody (HMFG1) and 
the nonspecific antibody (G250) are summarized in figure 3. 111In-HMFG1 was retained in 
the peritoneal cavity significantly better than 111In-G250. At 7 days postinjection, 40% of 
the injected dose of 111In-HMFG1 was still present i.p. versus only 5% of the injected dose 
for 111In-labeled control antibody G250 (P<0.001). At all time points, at least 80% of 
111In-HMFG1 in the ascitic fluid was cell-associated, with a maximum of 98% (7 days p.i.), 
while the major fraction of 111In-G250 was not cell-associated. 
The better retention of the 111In-HMFG1 antibody in the peritoneal cavity could also be 
visualized scintigraphically as shown in figure 4. The images of the mice that received 
111In-HMFG1 show that the 111In-HMFG1 activity is mainly localized in the peritoneal 
cavity throughout the study (0-168 h). In contrast, the images of the mice that received 
the nonspecific antibody, 111In-G250, show that from 24 h onwards a significant fraction 
of the 111In-G250 activity is localized outside the peritoneal cavity. 
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Figure 3. Abdominal retention of 111In-radiolabeled antibody HMFG1 compared to 111In-
radiolabeled antibody G250 (cell-associated activity and activity in the supernatant) in 
BALB/c nude mice with i.p. growing OVCAR-3 ovarian carcinoma cells (mean ± SD). 
Radiolabeled antibodies were injected at 0 h p.i.; at this time point retention was set at 
100%. 
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Figure 4. Scintigraphic images of mice with i.p. growing OVCAR-3 ovarian carcinoma 
following injection of 370 MBq 111In-HMFG1 (left) and 111In-G250 (right). Note that the 
111In-HMFG1 activity is predominantly retained in the peritoneal cavity, while a significant 
fraction of the 111In-G250 activity is localized outside the peritoneal cavity  
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Survival Study 
Relatively early after injection of the radiolabeled antibody preparations a total of six mice 
died: three mice treated with  90Y-G250 and three mice treated with 186Re-HMFG1 died in 
the first week p.i. for unknown reasons. It is unlikely that these mice died due to the 
effects of the radiation, because in the experiments to determine the MTD mice died 
between 2 and 4 weeks after injection of the radiolabeled antibody preparations. Three 
additional mice developed subcutaneous tumor growth at the site of injection without 
formation of ascites necessitating euthanasia (one mouse injected with 90Y-HMFG1 i.p. at 
17 weeks p.i., one mouse injected with 90Y-HMFG1 i.v. at 15 weeks p.i., one mouse 
injected with 186Re-HMFG1 at 10 weeks p.i.). These mice were excluded from the 
analysis. 
Mice that received radiolabeled HMFG1 i.p. showed a statistically significant longer 
survival than the mice that received no treatment at all (P<0.0001) (figure 5). 
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Figure 5. Kaplan-Meier survival plot of BALB/c nude mice with i.p. growing OVCAR-3 
ovarian carcinoma. Each experimental group consisted of 10 mice and received a 
treatment as shown in Table I. The arrow indicates the time the radiolabeled antibody 
preparations were administered. 
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Although the group that received 186Re-HMFG1 contained the highest percentage of long-
time survivors (three of six), the result of this RIT regimen was not statistially different 
from that after i.p. injection of 90Y-HMFG1 or 131I-HMFG1 (one of nine and two of ten long-
time survivors, respectively). Dissection of the long-time survivors did not reveal any 
evidence of tumor growth in these mice. All other treatments did not reveal any long-term 
survivors, including i.v. administered 90Y-HMFG1 and i.p. administered 90Y-labeled control 
antibody G250. Treatment with i.p. 90Y-HMFG1 led to a significantly better survival 
compared to administration of this compound via the i.v. route (P<0.0001). 
 
 
Discussion 
 
In athymic mice with i.p. growing ovarian carcinoma xenografts i.p. treatment with 90Y-
HMFG1 resulted in a statistically significant better survival than treatment with the same 
activity dose of a 90Y-labeled irrelevant antibody, while the latter treatment proved 
statistically better than no treatment at all. Each of the three radiolabeled HMFG1 
preparations (90Y-HMFG1, 186Re-HMFG1 and 131I-HMFG1) apparantly caused complete 
eradication of the i.p. growing tumors in a few mice. Although treatment with 186Re-
HMFG1 resulted in the highest percentage of survivors (50%), this was not significantly 
different from the other two preparations. In addition, the 90Y-HMFG1 was more potent 
when it was administered via the i.p. route. The selection of the most optimal 
radionuclide could be relevant for RIT. In the past few years new β emitting radionuclides 
have become available covering a wide range of radiation energies and radiation half-
lives. Here we compared 90Y (βmax 2.3 MeV, t½ 64 h), 186Re (βmax 1.1 MeV, t½ 91 h) and 
131I (βmax 0.6 MeV, t½ 192 h). Other β emitting radionuclides presently used for 
radioimmunotherapy include 188Re (βmax 2.1 MeV, t½ 17 h) (15), 177Lu (βmax 0.5 MeV, t½ 
161 h) (16) and 67Cu (βmax 0.6 MeV, t½ 62 days).17 High energy β radiation  with a 
corresponding long penetration range in tissue is less efficient when treating tumors with 
a relatively small diameter as most energy is deposited outside the lesion (e.g. in a tumor 
with a radius of 1.3 mm 77% of 90Y β radiation is deposited outside the tumor).18 
Therefore high-energy particles such as 90Y and 188Re are considered more appropriate 
for the treatment of larger tumors whereas low-energy particles such as 177Lu and 131I 
could be more efficient for the treatment of smaller tumors.19 Patients in complete 
clinical remission of ovarian cancer after surgery and chemotherapy have at the most 
minimal residual disease that can not be detected by physical examination or computer 
tomography. 
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In the present model the tumor burden consisted of cell clusters in ascitic fluid and small 
omental solid tumor depositions. The use of the specific antibody 90Y-HMFG1 resulted in 
better survival than the use of a 90Y-labeled irrelevant antibody. When present in the 
intraperitoneal cavity both radioimmunoconjugates expose the tumor cells to the β 
emissions of the 90Y radionuclide, and thus can exert a cytotoxic effect. However, as 
shown in the biodistribution study, the specific antibody HMFG1 had a higher residence 
time in the peritoneal cavity than the non-specific antibody G250, due to binding to the 
OVCAR-3 cells. As a result 90Y-HMFG1 caused a higher radiation dose to the tumor cells 
than 90Y-G250, resulting in a better survival of the mice that were treated with 90Y-
HMFG1. 
Studies in mice20 as well as studies in ovarian carcinoma patients21 have shown that 
ascitic tumor cells are better targeted after i.p. injection of radiolabeled antibodies, 
whereas larger i.p. implants are better reached after i.v. administration. In a recent study, 
patients suspected of having primary or recurrent ovarian carcinoma were simultaneously 
injected i.v. and i.p. with 125I/131I-labeled chimeric antibody MOv18.22 In this study 
antibody uptake in i.p. located tumor deposits was independent of the route of 
adminstration. Theoretically, ascitic tumor cells are optimally targeted by i.p. 
administered antibodies. The  results of the present study support this hypothesis as i.v. 
administered 90Y-HMFG1 did not cause any delay of the growth of the tumor. In patients 
with ascitic tumor cells and very small tumor deposits it seems therefore advisable to use 
a specific, i.p. administered, radiolabeled monoclonal antibody. If larger solid tumor 
depositions are present, the preferential route of administration remains to be 
determined. 
The prognosis of patients with high stage ovarian carcinoma is still very poor. A small gain 
in treatment outcome offered by the replacement of cyclophosphamide by taxanes in 
first-line chemotherapeutic multidrug treatment was shown more than five years ago.23 
There is an urgent need for more effective treatment strategies. Phase II studies indicate 
that i.p. RIT can improve the survival of ovarian carcinoma patients.24,25 Currently the 
therapeutic potential of i.p. administered 90Y-labeled murine HMFG1 in ovarian cancer 
patients with no evidence of residual disease is investigated in a multicenter phase III 
study. Further optimization of RIT might be feasible using new cytotoxic radionuclides with 
more optimal β radiation characteristics or new antibody delivery strategies like 
pretargeting.26  
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Abstract 
 
The αvβ3 integrin is expressed on proliferating endothelial cells such as those present in 
growing tumors, as well as on tumor cells of various origin. Tumor-induced angiogenesis 
can be blocked in vivo by antagonizing the αvβ3 integrin with small peptides containing 
the Arg-Gly-Asp (RGD) amino acid sequence. This tripeptidic sequence, naturally present 
in extracellular matrix proteins, is the primary binding site of the αvβ3 integrin. Because of 
selective expression of αvβ3 integrin in tumors, radiolabeled RGD-peptides are attractive 
candidates for αvβ3 integrin targeting in tumors. We studied the in vivo behavior of the 
radiolabeled dimeric RGD-peptide E-[c(RGDfK)]2 in the NIH:OVCAR-3 s.c. ovarian 
carcinoma xenograft model in BALB/c nude mice. Conjugation of the 1,4,7,10-
tetraazadododecane-N,N’,N’’,N’’’-tetraacetic acid (DOTA) and hydrazinonicotinamide 
(HYNIC) chelators enabled efficient radiolabeling with 111In/90Y and 99mTc, respectively. 
The radiolabeled peptide was rapidly excreted renally. Uptake in nontarget organs such 
as liver and spleen was considerable. Tumor uptake peaked at 7.5 % injected dose (ID)/g 
(111In-DOTA-E-[c(RGDfK)]2) or 6.0 %ID/g (99mTc-HYNIC-E-[c(RGDfK)]2) at 2 and 1 h 
postinjection (p.i.), respectively. Integrin αvβ3 receptor binding specificity was 
demonstrated by reduced tumor uptake after injection of the scrambled control peptide 
111In-DOTA-E-[c(RDKfD)]2 (0.28 %ID/g at 2 h p.i.) and after coinjection of excess 
nonradioactive 115In-DOTA-E-[c(RGDfK)]2 (0.22 %ID/g at 2 h p.i.). A single injection of 90Y-
DOTA-E-[c(RGDfK)]2 at the maximum tolerated dose (37 MBq) in mice with small s.c. 
tumors caused a significant growth delay as compared with mice treated with 37 MBq 
90Y-labeled scrambled peptide or untreated mice (median survival of  54 versus 33.5 
versus 19 days, respectively). In conclusion, the radiolabeled RGD-peptides 111In-DOTA-E-
[c(RGDfK)]2 and 99mTc-HYNIC-E-[c(RGDfK)]2 demonstrated high and specific tumor uptake 
in a human tumor xenograft. Injection of 90Y-DOTA-E-[c(RGDfK)]2 induced a significant 
delay in tumor growth. Potentially these peptides can be used for peptide receptor 
radionuclide imaging as well as therapy. 
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Introduction 
 
Integrins are an important class of transmembrane molecules involved in cell-cell and 
cell-matrix interaction.1 Integrins are heterodimeric glycoproteins consisting of an α-
subunit and a β-subunit. Integrin αvβ3 is expressed on proliferating but not on quiescent 
endothelial cells. In addition, αvβ3 can be found on tumor cells of various origin. Integrin 
αvβ3 mediates cellular adhesion to vitronectin, fibrinogen, laminin, collagen, von 
Willebrand factor, or osteopontin through their exposed RGD amino acid sequence.2 
Integrin αvβ3 mediated cell adhesion may affect cell cycle kinetics or may cause 
anchorage dependent cell death or apoptosis. 
Because it has been recognized that the growth of virtually all solid tumors is dependent 
on angiogenesis, studies have focused on agents that could inhibit this process.3 It was 
found that a monoclonal antibody directed towards the αvβ3 integrin blocked 
angiogenesis in human melanoma and breast tumor xenografts4 without effecting pre-
existing blood vessels.5 Similar effects could be achieved with small peptides containing 
the RGD amino acid sequence.6,7 Because of its highly restricted expression and its vital 
role in angiogenesis, the αvβ3 integrin is an attractive candidate in anticancer strategies. 
Radiolabeled receptor-binding peptides have emerged as an important class of 
radiopharmaceuticals.8 Recently, several studies reported the development of 
radiolabeled RGD-peptides for αvβ3 integrin receptor targeting.9-14 In animal experiments, 
specific tumor targeting was reported in mice with melanoma, breast, and osteosarcoma 
cancer10,13,14, and in rats with pancreatic tumors.11 
Here we studied the tumor targeting potential of both a 111In and 99mTc-radiolabeled 
dimeric RGD-peptide, derivatized with the chelators DOTA and HYNIC, in a s.c. ovarian 
carcinoma xenograft mouse model. In addition, the therapeutic potential of the 90Y-
labeled RGD-peptide was assessed. 
 
 
Materials and Methods 
 
RGD-peptides 
Two cyclic pentapeptides c(RGDfK) were linked via a glutamic acid residue resulting in 
the peptide E-[c(RGDfK)]2 with a molecular weight of Mr 1319. This peptide had a high 
affinity for the αvβ3 integrin (IC50=0.9 nM) and a low affinity for the αvβ5 and αIIBβ3 
integrin (IC50>10mM).15 The compound was derivatized with the chelators DOTA (Fig. 1) 
or HYNIC to allow labeling of the peptide with 111In/90Y or 99mTc/188Re, respectively. A 
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DOTA-conjugated peptide with the scrambled amino acid sequence E-[c(RGKfD)]2 was 
used as a control peptide in these studies. 
 
Radiolabeling of the RGD-peptides 
DOTA-E-[c(RGDfK)]2 was radiolabeled with 111In to obtain 111In-DOTA-E-[c(RGDfK)]2  
(RP686, Bristol-Myers Squibb, Billerica, MA, USA). Briefly, 250 µg of DOTA-E-[c(RGDfK)]2 
was dissolved in 4.5 ml of 0.25 M ammoniumacetate buffer (pH 7.0), and 160 MBq of 
111InCl3 (Mallinckrodt, Petten, the Netherlands) was added. The mixture was heated for 
15 min at 100 °C. Colloid content was checked using silicagel instant thin layer 
chromatography (Gelman-Sciences, Ann-Arbor, MI, USA) with 0.9% NaCl as the mobile 
phase. The RCP was determined by RP-HPLC (HP 1100 series; Hewlett Packard, Palo Alto, 
CA, USA) using a C18 column (RX-C18, 4.6 x 250 mm, Zorbax) eluted with a 13% 
acetonitrile in 25 mM phosphate buffer (pH 6.0) at 1.0 ml/min. The radioactivity of the 
eluate was monitored using an in-line radiodetector (Flo-One Beta series A-100, 
Radiomatic, Meriden, CT, USA). The scrambled sequence control peptide DOTA-E-
[c(RGKfD)]2 was radiolabeled with 111InCl3 and analyzed analogously. 
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Figure 1. Structural formula of the 111In-labeled, DOTA conjugated, dimeric cyclic RGD-
peptide 111In-DOTA-E-[c(RGDfK)]2. 
 
 
90Y-DOTA-E-[c(RGDfK)]2 (RP697, Bristol-Myers Squibb) was prepared by adding 370 MBq 
90YCl3 (NEN, Boston, MA) to 100 µg DOTA-E-[c(RGDfK)]2 dissolved in 450 µl 0.25 M 
ammoniumacetate buffer (pH 7.0). Again the mixture was heated at 100 °C for 15 min. 
Quality control was carried out as described for the 111In-labeled peptide. 
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HYNIC-E-[c(RGDfK)]2 was radiolabeled with 99mTc to obtain 99mTc-HYNIC-E-[c(RGDfK)]2 
(RP593, Bristol-Myers Squibb). Briefly, 20 µg of HYNIC-E-[c(RGDfK)]2 was dissolved in 
200 µl 0.25 M succinate buffer (pH 5.0). Then 6.5 mg of tris(hydroxymethyl)methylglycine 
(Fluka, Buchs, Switzerland) and 5 mg of triphenylphosphine-3,3’,3’’-trisulfonate (Sigma, 
St. Louis, MO, USA) were added in 500 µl water. After adding 0.85 GBq 99mTcO4-, the 
reaction mixture was heated at 100 °C for 15 min. RCP was checked as described above. 
For the RP-HPLC procedure, a gradient of 12-15% acetonitrile in 25 mM phosphate buffer 
(pH 6.0), over 30 min, was used at a flow rate of 1.0 ml/min. The αvβ3 binding capacity of 
the radiolabeled peptides was confirmed in an in vitro cell binding assay. IGROV-1 cells 
were trypsinized and preincubated in Tris-HCl (pH 7.4), supplemented with 1 mM MgCl2, 
1 mM CaCl2, 1 mM MnCl2, and 1% BSA for 15 min at 0 °C. A fixed amount of radiolabeled 
peptide (105 cpm) was incubated with increasing cell concentrations (1.2 x 107 - 2 x 108 
cells/ml, 0.5 ml per incubation) in RPMI medium (Life Technologies, Inc., Breda, The 
Netherlands) supplemented with 0.5 % BSA and 0.05% NaN3. Nonspecific binding was 
determined by coincubating an excess of unlabeled peptide. The receptor binding fraction 
of the radiolabeled peptides at infinite cell concentration as derived from the modified 
Lineweaver-Burke plot, exceeded 70%.  
 
Animal model 
A cell suspension of NIH:OVCAR-3 ovarian carcinoma cells was prepared (108 cells/ml). A 
total of 0.1 ml of the cell suspension was injected s.c. in the right upper flank of 6-8 
week-old female nude BALB/c mice. Two weeks after inoculation of the tumor cells, when 
tumors weighed 0.1-0.4 g, mice received injections of the 111In or the 99mTc-labeled 
peptides. The therapeutic doses of 90Y-labeled peptides were injected 12 days post 
inoculation. The studies were approved by the local Animal Welfare Committee. The 
NIH:OVCAR-3 cells express the αvβ3 integrin as determined by flowcytometric analysis 
following staining with a murine monoclonal antibody against αvβ3 (LM609). 
 
Biodistribution Studies 
In all experiments 5 mice/time point were used, and 370 kBq 111In-DOTA-E-[c(RGDfK)]2 
(0.5 µg) or 1.7 MBq 99mTc-HYNIC-E-[c(RGDfK)]2 (0.04 µg) were i.v. injected. One, 2, 4, 8 
and 24 hours after injection of 111In-DOTA-E-[c(RGDfK)]2 and 99mTc-HYNIC-E-[c(RGDfK)]2, 
mice were anesthetized with ether. After blood was collected from the retro-orbital 
venous plexus, mice were killed by cervical dislocation. Tissues (tumor, muscle, lung, 
spleen, kidney, liver, small intestine) were dissected and weighed. The activity in tissues 
and injection standards was measured in a shielded well-type scintillation gamma 
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counter (1480 Wizard, Wallac Oy, Turku, Finland) and expressed as the percentage of the 
injected dose/gram tissue (%ID/g). Using these data, tumor-to-blood ratios were 
calculated. 
 
Scintigraphic imaging 
Mice with s.c. NIH:OVCAR-3 tumors (0.5 g) were anesthetized by enflurane inhalation 
anesthesia and placed prone on a single head gamma camera equipped with a parallel 
hole medium energy collimator (Siemens Orbiter; Siemens Inc., Hoffman Estate, IL, USA). 
Images were acquired 2 h after injection of 1.8 MBq 111In-labeled peptides and stored 
digitally in a 256 × 256 matrix. 
 
Receptor Specificity Studies 
The receptor-mediated localization of the 111In-labeled RGD-peptide was investigated by 
determining the biodistribution of 111In-DOTA-E-[c(RGDfK)]2 in mice with OVCAR-3 tumors 
in the presence or absence of a 1000-fold excess of nonradioactive 115In-DOTA-E-
[c(RGDfK)]2 . Biodistribution of the radiolabel was determined as described above at 2 h 
p.i. in 5 mice/group. In an additional experiment the biodistribution of 111In-DOTA-E-
[c(RGDfK)]2 was compared to that of the scrambled peptide 111In-DOTA-E-[c(RGKfD)]2. The 
peptide dose of both peptides was 0.5 µg, and the biodistribution of the radiolabel was 
determined as described above at 30 min, 1, 2 and 4 h p.i. 
 
MTD of 90Y-DOTA-E-[c(RGDfK)]2 
The MTD in nontumor-bearing female nude BALB/c mice was determined by i.v. injection 
of escalating activities of 90Y-DOTA-E-[c(RGDfK)]2. Each dose was tested in three mice. 
The doses tested were 22, 30, 37, 44 and 52 MBq 90Y-DOTA-E-[c(RGDfK)]2/mouse. Body 
weight and survival of the mice were monitored twice weekly during the whole 
observation period. Body weight and survival of the mice were monitored twice weekly 
during the whole observation period. Peripheral blood counts were checked once weekly 
for 3 weeks together with blood creatinine and blood ureum nitrogen. The MTD was set 
on the dose below the first dose that caused severe loss of body weight (>20%) or death 
of one or more animals of a dose group. 
 
Peptide Receptor Radionuclide Therapy 
Mice with s.c. OVCAR-3 tumors received 37 MBq 90Y-DOTA-E-[c(RGDfK)]2, or 37 MBq 90Y-
DOTA-E-[c(RGKfD)]2. A group of mice that did not receive any treatment served as control 
group. The size of the tumors was measured twice weekly in three dimensions using a 
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caliper. The volume was estimated assuming the tumors were elipsoids, using the 
formula: volume = 4/3π × ½ length × ½ width × ½ height). At the time of the injection, 
the volume of the s.c. tumors ranged from 27 to 150 mm3. At least 7 mice/experimetal 
group were used. 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 3.0 (GraphPad Software, San 
Diego, CA, USA). The biodistribution data were analyzed using the one-way ANOVA test. 
The level of significance was set at P=0.05.  
 
 
Results 
 
Radiolabeling of RGD-peptides 
Instant thin layer chromatography analysis indicated that colloid content of the 
radiolabeled preparations did not exceed 2%. The elution profile of 111In-DOTA-E-
[c(RGDfK)]2 showed a RCP exceeding 90% with the product eluting in a single peak with a 
retention time of 14 min (Fig. 2). 99mTc-HYNIC-E-[c(RGDfK)]2 typically revealed two 
symmetric peaks at 17 and 20 min (Fig. 2), representing the two diastereomers of the 
compound (16). The RCP of 99mTc-HYNIC-E-[c(RGDfK)]2, 111In-DOTA-E-[c(RGKfD)]2, 90Y-
DOTA-E-[c(RGDfK)]2 and 90Y-DOTA-E-[c(RGKfD)]2 also exceeded 90%. Minor impurities 
were observed in the elution profile with a retention time of ~10 min.  
 
Biodistribution and Imaging Studies 
On the scintigraphic images acquired at 2 h after the injection of both the 111In-DOTA-E-
[c(RGDfK)]2 and 111In-DOTA-E-[c(RGKfD)]2, the kidneys and the bladder are the organs 
with the highest activity levels, illuminating the renal excretion pattern of the radiolabeled 
peptides (Fig. 3). The subcutaneous tumors were visualized on the images of the mice 
that received 111In-DOTA-E-[c(RGDfK)]2, but not on the images of mice that received 
injections with 111In-DOTA-E-[c(RGKfD)]2. 
The biodistribution of 111In-DOTA-E-[c(RGDfK)]2 and 99mTc-HYNIC-E-[c(RGDfK)]2 in mice 
with NIH:OVCAR-3 tumors is summarized in Fig. 4. Following injection of both agents, the 
radioactivity cleared rapidly from the blood. Uptake of the radiolabeled peptides in the 
tumor was rapid and high. The highest uptake in the tumor was obtained with 111In-DOTA-
E-[c(RGDfK)]2 at 2 h p.i. at 7.5 %ID/g, whereas the highest tumor uptake of 99mTc-HYNIC-
E-[c(RGDfK)]2 was found at 1 h p.i. at 6.0 %ID/g. In the course of time, the tumor-to-blood 
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99mTc-HYNIC-E-[c(RGDfK)]2 
 
111In-DOTA-E-[c(RGDfK)]2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. RP-HPLC profiles of 111In-DOTA-E-[c(RGDfK)]2 (top) and 99mTc-HYNIC-E-
[c(RGDfK)]2 (bottom) showing a radiochemical purity exceeding 90% of both conjugates. 
Note the two peaks (doublet) in the elution profile of 99mTc-HYNIC-E-[c(RGDfK)]2 reflecting 
the two stereoisomers of this radiolabeled compound. 
 
 
A B
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Scintigraphic image of three athymic BALB/c mice with a subcutaneous 
NIH:OVCAR-3 tumor in the right upper flank 2 h after injection of 1.8 MBq 111In-DOTA-E-
[c(RGDfK)]2 (posterior-anterior view) (A). Mice received 1.8 MBq of the 111In-labeled 
peptide via the tail vein. Tumors are visualized (arrows). Activity in the kidneys and 
bladder reflects the renal excretion of the radiolabeled peptide. The tumor was not 
visualized in the mice that received 1.8 MBq of the 111In-labeled scrambled peptide 
DOTA-E-[c(RGKfD)2] (B). 
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ratios rose up to 92 for 111In-DOTA-E-[c(RGDfK)]2 and 26 for 99mTc-HYNIC-E-[c(RGDfK)]2. 
Remarkably, there was considerable uptake of both peptides in various normal tissues 
such as spleen, liver, and kidney. Muscle and lung tissues had relatively low activity 
uptake. 
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Figure 4. Biodistribution and tumor-to-blood ratios of 111In-DOTA-E-[c(RGDfK)]2 (top) and 
of 99mTc-HYNIC-E-[c(RGDfK)]2 (bottom) in athymic mice with a s.c. NIH:OVCAR-3 tumors. 
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Receptor Specificity Studies 
Coinjection of a 1000-fold excess of nonradioactive 115In-DOTA-E-[c(RGDfK)]2 together 
with 0.5 µg of 111In-DOTA-E-[c(RGDfK)]2 resulted in a significant decrease of radioactivity 
in all dissected tissues, except the kidneys (Fig. 5). Uptake in the tumor was reduced 
most pronouncedly from 5.2 to 0.2 %ID/g. The control peptide 111In-DOTA-E-[c(RGKfD)]2 
showed a biodistribution profile highly similar to that of 111In-DOTA-E-[c(RGDfK)]2 in the 
presence of an excess of 115In-DOTA-E-[c(RGDfK)]2 (Fig. 6). Uptake of the scrambled 
peptide in the tumor was similarly low  (0.3 %ID/g, 1 h p.i.). Both experiments showed 
that the uptake and retention of  111In-DOTA-E-[c(RGDfK)]2 was receptor dependent in the 
tumor but also in several normal organs such as the spleen and the liver.  
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Figure 5. Biodistribution of 111In-DOTA-E-[c(RGDfK)]2 in the absence and presence of a 
1000-fold excess non-radioactive peptide at 2 h p.i. in athymic mice with s.c. NIH:OVCAR-
3 tumors. 
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Figure 6. Biodistribution of 111In-DOTA-E-[c(RGDfK)]2 (left) and the peptide with the 
scrambled amino acid sequence 111In-DOTA-E-[c(RGKfD)]2 (right) in athymic mice with 
s.c. NIH:OVCAR-3 tumors. 
 
 
MTD of 90Y-DOTA-E-[c(RGDfK)]2 
All mice injected i.v. with 22, 30 or 37 MBq 90Y-DOTA-E-[c(RGDfK)]2 survived at least 2 
months p.i. without any sign of weight loss (figure 7). After injection of 44 MBq and 52 
MBq 90Y-DOTA-E-[c(RGDfK)]2 the body weight of the mice rapidly fell <90% of the initial 
value. MTD was therefore set on 37 MBq 90Y-DOTA-E-[c(RGDfK)]2. The mice that received 
the highest activity doses showed a marked decrease in their hemoglobin levels as early 
as 5 days after injection. During the first 3 weeks p.i., there was no indication of severe 
bone marrow suppression (Fig. 7) nor of abnormal kidney function (creatine and blood 
ureum nitrogen levels were normal at all timepoints; data not shown). 
 
Peptide Receptor Radionuclide Therapy 
The growth curves of the two groups of mice that received the 90Y-labeled peptides and 
the control group are shown in Fig. 8. 
The tumor volume doubling time in the group that received 37 MBq of the αvβ3-binding 
peptide was 5.2 days, as  compared with 3.9 days in the group that received 37 MBq of 
the scrambled peptide. The tumor volume doubling time of the mice that did not receive 
any treatment was 3.2 days. In 50% of mice treated with 37 MBq 90Y-DOTA-E-[c(RGDfK)]2, 
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Figure 7. Whole-body weight, hemoglobin levels, leukocyte counts  and platelet counts  of 
the athymic BALB/c mice that received an i.v. injection with a therapeutic dose of 90Y-
DOTA-E-[c(RGDfK)2]. Three mice per dose level were used. Mice were killed when their 
whole-body weight loss exceeded more than 20% of their initial body-weight. 
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Figure 8. Kaplan-Meier plots of three groups of mice with NIH:OVCAR-3 s.c. tumors after 
i.v. injection of 37 MBq 90Y-DOTA-E-[c(RGDfK)]2 or 37 MBq 90Y- DOTA-E-[c(RGDfK)]2 and 
untreated controls. 
 
 
the volume of 50% of the tumors exceeded 1.0 cm3 after 54 days compared with 34 days 
for the group treated with the scrambled peptide (DOTA-E-[c(RGKfD)]2) labeled with the 
same activity dose of 90Y. In the group of mice that did not receive any treatment, the 
volume of 50% of tumors exceeded 1.0 cm3 after 19 days. The tumor growth in the three 
groups was significantly different (90Y-DOTA-E-[c(RGDfK)]2 versus 90Y-DOTA-E-[c(RGKfD)]2: 
P < 0.05; 90Y-DOTA-E-[c(RGDfK)]2 versus control: P < 0.01; 90Y-DOTA-E-[c(RGKfD)]2 versus 
controls: P < 0.05). In a separate experiment, it was established that an i.v. injection with 
the unlabeled DOTA-E-[c(RGDfK)]2 did not have any therapeutic effect in this model: the 
median survival of the mice that received 5 µg of unlabeled DOTA-E-[c(RGDfK)]2 (19 days) 
was similar to that of the mice that received injections with saline (15 days; P > 0.05).    
 
 
Discussion 
 
The present study showed that the radiolabeled RGD-peptides 111In-DOTA-E-[c(RGDfK)]2 
and 99mTc-HYNIC-E-[c(RGDfK)]2 are able to target tumor tissue after i.v. injection in a 
xenograft mouse model. As early as 2 h p.i., the concentration of the radiolabel in the 
tumor reached 7.5 %ID/g, which is relatively high as compared to other receptor binding 
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peptides in xenograft mouse models.8 Tumor-to-blood ratios reached 92 for 111In-DOTA-E-
[c(RGDfK)]2 and 26 for 99mTc-HYNIC-E-[c(RGDfK)]2 at 24 h after injection. Receptor-
mediated specificity of the tumor accumulation of the radiolabeled RGD-peptide for the 
αvβ3 integrin was demonstrated. Finally, peptide receptor radionuclide therapy using 90Y-
DOTA-E-[c(RGDfK)]2 caused a significant delay of growth of small tumors in mice.    
Other authors have shown that radiolabeled RGD-peptides can accumulate in animal 
model tumors. The iodinated monomeric RGD-peptide c(RGDyV) targeted M21 
melanoma, osteosarcoma and MaCaF breast carcinoma tumors, with a tumor uptake of 
up to 3.50 %ID/g at 10 minutes p.i.13 However, this peptide cleared via the hepatobiliary 
route, as indicated by high uptake in liver and intestines. By substituting the amino acid 
valine by a lysine and conjugating a hydrophilic sugar moiety to this amino acid, the 
peptide cleared renally.10 A similar phenomenon was recently described with the cyclic 
peptide c(RGDyK). This radioiodinated peptide cleared via the hepatobiliary route. 
However, when the ε-aminogroup of the lysine residue was substituted with 
diethylenetriaminepentaacetic acid  to allow labeling of the peptide with 111In, the peptide 
cleared exclusively via the kidneys. In a rat model this 111In-labeled peptide showed 
preferential tumor accumulation in syngeneic CA20948 pancreatic tumors.11 Our DOTA, 
as well as HYNIC-conjugated radiolabeled peptides, almost exclusively cleared via the 
preferred renal pathway. 
Several non-tumor tissues such as liver and spleen also showed αvβ3 integrin receptor-
mediated uptake, suggesting that the peptide also binds specifically to a cell surface 
molecule expressed on these tissues. However, to our knowledge, the expression of αvβ3 
integrin in these murine tissues has not been documented. Recently, αvβ3 expression in 
microvessels of the lung and to a lesser extent the liver of the rat has been 
documented.17 Localization of the radiolabeled peptides in nontumor tissues may limit 
their imaging, as well as their therapeutic application. The physiologic uptake in the liver, 
spleen, and kidneys may hamper imaging of abdominal tumor lesions and will limit the 
activity dose that can be administered safely. Future studies will have to show whether 
this phenomenom also plays a role in other species or whether this interaction can be 
prevented by modifying the structure of the peptide.   
We found marked differences in the biodistribution of 111In-DOTA-E-[c(RGDfK)]2 as 
compared with the 99mTc-HYNIC-E-[c(RGDfK)]2 peptide. In particular, the blood level and 
the uptake in the kidneys were higher for the 99mTc-labeled peptide. It has been shown 
that the blood level of a peptide can be markedly affected by the chelator and even by 
the coligand of the radiolabeled peptide: interaction of HYNIC-Tc-coligand complex with 
serum proteins has been described and this interaction may affect the circulatory half-life 
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and the biodistribution of the radiolabeled compound.18 This may explain the higher 
blood level of 99mTc-HYNIC-[c(RGDfK)]2 as compared with the 111In-labeled peptide. The 
enhanced kidney retention of the 99mTc-labeled peptide may be attributable to the more 
effective reabsorption of this peptide by the tubular cells. After glomerular filtration, small 
peptides are reabsorbed from the primary urine by the tubular cells.19 It has been 
hypothesized that peptides adhere to the luminal surface of the tubular cells by 
electrostatic interaction: the peptide may bind via its positive charges to the negatively 
charged receptors on the tubular cell membrane. Subsequently the peptide is 
internalized by receptor-mediated endocytosis, and the radiolabeled peptide is degraded 
in lysosomes. The DOTA-conjugated peptide may present less positive charges as 
compared with the HYNIC-conjugated peptide, and this may explain the difference in 
renal uptake of the two peptides.  
In addition, it remains to be determined whether RGD-peptides are retained in tumor 
tissue because of the interaction with αvβ3 integrin expressed on the neovasculature or 
on the tumor cells or on a combination of both cell types. In this respect, it is unclear 
whether RGD-peptides actually target angiogenesis in growing tumors or αvβ3 expression 
of tumor cells.  
This is the first report on the therapeutic potential of radiolabeled RGD-peptides in mice. 
We showed that the 90Y-labeled DOTA-E-[c(RGDfK)]2 peptide induced a significant delay in 
the growth of a s.c. human ovarian carcinoma xenograft. Our preliminary studies suggest 
that the approach is particularly effective against relatively small tumors (< 150 mm3). 
Small peptides labeled with β-emitting radionuclides may cause a high radiation dose to 
the kidneys. However the 111In-labeled RGD-peptide showed relatively low retention in the 
kidneys. Although the kidneys are relatively radiation resistant, irreversible radiation 
damage of kidney function may occur at high radiation doses. In external beam 
radiotherapy, a dose of 23 Gy (2300 rad) is considered the maximum tolerated radiation 
dose to the kidneys. The radiation dose to the kidneys from internal radionuclide therapy 
that does not give rise to any (acute or chronic) nephrotoxicity is still a matter of debate.20 
The choice of the radionuclide, more specifically the range of the emitted particles in 
tissue, is an important factor that may affect the renal toxicity of the radiolabeled peptide. 
Our future studies will focus on the selection of the most optimal radionuclide for peptide 
receptor radionuclide therapy with RGD-peptides. Besides β-emitters like 188Re, 177Lu and 
67Cu, also α-emitters (213Bi) as well as Auger emitters (111In, 67Ga) could be considered. 
In conclusion, these studies indicate that peptide radionuclide receptor therapy based on 
the targeting of the αvβ3 integrin by radiolabeled RGD-peptides causes a significant 
growth delay in a s.c. xenograft mouse model. Optimization of this therapy by increasing 
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the number of injections and the choice of radionuclide could further improve therapeutic 
potential of the peptides. 
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Chapter 4 
Abstract 
 
Objective: Arginine-glycine-aspartic acid (RGD) peptides can preferentially target 
malignant tumors by selectively binding the αvβ3 integrin expressed on sprouting 
endothelial cells. To allow estimation of the dosimetry of the RGD-peptide E-[c(RGDfK)]2 
derivatized with the chelator 1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid 
(DOTA) and radiolabeled with the pure β-emitter 90Y, two surrogates were studied: the 86Y-
labeled analogue as the gold standard and the more readily available 111In-labeled 
analogue. 
Methods: Five Beagle dogs consecutively received 240 MBq 111In-DOTA-E-[c(RGDfK)]2 and 
74 MBq 86Y-DOTA-E-[c(RGDfK)]2. Blood pharmacokinetics were determined and whole 
body images were acquired using a dual head gamma camera and PET, respectively, 
directly post injection, and 1, 2 and 3 days post injection. After correction for attenuation 
and scatter, radiation doses to relevant organs were calculated from their residence 
times using MIRDOSE3. 
Results: Blood pharmacokinetics of 111In-DOTA-E-[c(RGDfK)]2 and 86Y-DOTA-E-[c(RGDfK)]2 
were comparable. The predicted doses of these two peptides to relevant organs were 
similar for all organs with exception of the lungs.   
Conclusion: Dose estimates to relevant organs after injection of the RGD-peptide 90Y-
DOTA-E-[c(RGDfK)]2 can be accurately predicted using readily available 111In-labeled 
peptide. 
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Introduction 
 
The αvβ3  integrin is a heterodimeric transmembrane protein expressed on sprouting 
endothelial cells providing a binding opportunity to arginine-glycine-aspartic acid (RGD) 
amino acid sequences present in extracellular matrix proteins. The αvβ3  integrin plays an 
important role in the proces of angiogenesis in malignant tumors.1 Radiolabeled RGD-
peptides could potentially be used as vehicles to target solid tumors with αvβ3  integrin 
positive neovasculature for imaging and peptide receptor radionuclide therapy (PRRT)].2 
90Yttrium (90Y) is widely used as a β--emitting radionuclide in experimental radionuclide 
therapies, but the absence of γ or positron radiation precludes an accurate estimate of 
the radiation dose to relevant organs. For this reason, 111Indium (111In) and 86Yttrium 
(86Y) have been used as surrogates.3 111In is attractive because it is widely available and 
can be imaged with a gamma camera but it could cause minor alterations in charge or 
configuration of radiolabeled peptides. 86Y is sparcely available and necessitates positron 
emitting tomography (PET). 
The aim of this study was to perform a comparative dosimetrical analysis between the 
111In-labeled and the 86Y-labeled RGD-peptide E-[c(RGDfK)]2 derivatized with the chelator 
1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tertaacetic acid (DOTA). If the dosimetry 
based on the images acquired from the 111In-labeled peptide would reflect that of the 86Y-
labeled peptide, future evaluation could be performed using the peptide labeled with 
111In. 
 
 
Materials and Methods 
 
Animals 
Five healthy Beagle laboratory dogs (10.5-13.4 kg) were used. Before each imaging 
procedure, anaesthesia of the dogs was induced with intravenously administered 
pentobarbital. A tracheal tube and bladder catheter were installed. The protocol was 
approved by the local Animal Wellfare Committee. 
 
RGD peptide and radiolabeling 
E-[c(RGDfK)]2 is a dimeric RGD-peptide consisting of two cyclic pentapeptides c(RGDfK) 
linked via a glutamic acid residue. The peptide has a high affinity for the αvβ3 integrin 
(IC50=0.9nM). E-[c(RGDfK)]2 is derivatized with the chelator DOTA. 
For each dog, 240 MBq 111InCl3 (Mallinckrodt Medical BV, Petten, the Netherlands) or 74 
MBq 86Y-(NO3)3 (Cyclotron Unit, Universtät Mainz, Mainz, Germany) was added to 300 µg 
DOTA-E-[c(RGDfK)]2  dissolved in 5.9 ml 0.25 M ammoniumacetate buffer, pH 7.0. After 
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heating for 15 minutes at 100 °C, radiochemical purity was assessed by reversed-phase 
high performance liquid chromatography (HP 1100 series, Hewlett Packard, Palo Alto, CA, 
USA) using a C18 column (RX-C18, 4.6mm*25cm, Zorbax, Palo Alto, CA, USA) at a flow of 
1 ml/min of a 13% acetonitrile dilution in 25 mM phosphate buffer pH 6.0. 
Radiochemical purity of both radiolabeled compounds exceeded 90%. 
 
Imaging procedure 
111In-DOTA-E-[c(RGDfK)]2 
Using a dual-head gamma camera (Siemens MultiSpect2, Siemens, Hoffman Estates, IL, 
USA) equipped with parallel-hole medium energy collimators, first a whole-body 
transmission scan was made using a perspex flood source (von Gahlen, Didam, the 
Netherlands) filled with 150 MBq 111In-DOTA-E-[c(RGDfK)]2. Subsequently, 240 MBq = 
300 µg 111In-DOTA-E-[c(RGDfK)]2 was intravenously injected and whole body images 
(anterior and posterior view) was acquired at 5 min, 24, 48 and 72 h post injection (p.i.) 
(bedspeed 4 cm/min). 
 
86Y-DOTA-E-[c(RGDfK)]2 
The 86Y-labeled peptide was injected 2 weeks after injection of the 111In-labeled 
compound. A dedicated, rotating half-ring PET-scanner (ECAT-ART, Siemens/CTI, 
Knoxville, TN, USA) was used for data acquisition. Five minutes, 24, 48 and 72 h after 
intravenous injection of 74 MBq = 300 µg 86Y-DOTA-E-[c(RGDfK)2], emission and 
transmission images of the whole body were made (10 min per bedposition). Images 
were corrected for attenuation and reconstructed using the ordered-subsets expectation 
maximization (OSEM) algorithm. 
 
Blood measurements 
Blood samples were taken at 1, 5, 10, 30 min and 1, 4, 24, 48 and 72 h p.i. The 
radioactivity in samples and injection standards was measured in a shielded well-type 
scintillation gamma counter (Wizard, Pharmacia, Oy, Finland) and expressed as the 
percentage of the injected dose per gram (%ID/g). From these data the dose to the red 
marrow was calculated according to the method reported by Shen et al.4 
 
Dosimetric Analysis 
111In-DOTA-E-[c(RGDfK)]2 
Conjugate view analysis was performed. Regions of interest (ROIs) were drawn manually 
on anterior and posterior images identifying total body, liver, spleen, left and right kidney, 
bladder, right lung, left shoulder red marrow and total vertebral column red marrow. 
Background correction was applied on those organs that did not fill the total transverse 
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diameter of the body. The geometric mean of the background corrected anterior and 
posterior counts was calculated. The attenuation factor per organ was derived by dividing 
the organ specific counts per pixel of the transmission scan of the dog by the counts per 
pixel of the empty bed. The attenuation corrected counts per organ were calculated by 
dividing the geometric mean by the attenuation factor. Time-activity curves and the area 
under the curves (AUC) were calculated using the trapezoid method assuming that the 
tail of the curve was solely determined on physical decay. Residence times were 
corrected for physical decay of 90Y and imported in MIRDOSE3 for a male adult of 70 kg. 
A dynamic bladder model was applied with a 3 h voiding frequency in a 2-compartment 
model and a strictly renal excretion pattern. Concerning the red marrow, a percentage red 
marrow in the left shoulder and the total vertebral column of 2.5 and 28% of the total red 
marrow mass was assumed, respectively. 
 
86Y-DOTA-E-[c(RGDfK)]2 
Relevant organs were rebuilt by selecting all coronal planes (0.7 cm per plane) that 
included the respective organ. In a transverse view ROI of these organs were drawn 
manually for liver, spleen, kidneys, right lung, shoulder and vertebral column. After 
correction for physical decay the residence times were calculated from time-activity 
curves and imported in MIRDOSE3. 
 
Statistical analysis 
All data were expressed as mean ± SD and were analyzed using paired t-tests. The level 
of significance was set at 0.05. 
 
 
Results 
 
Imaging procedure 
Examples of 111In-DOTA-E-[c(RGDfK)]2 and 86Y- DOTA-E-[c(RGDfK)]2 images are shown in 
figure 1. 
 
Blood measurements 
Blood activity data are summarized in figure 2. The t½(α) and t½(β) of the 111In-labeled 
and the 86Y-labeled compound were not significantly different (t½(α) = 18.6 ± 8.9 and 
16.2 ± 4.7 min, respectively; t½(β) = 44.0 ± 17.1 and 30.0 ± 14.1 hour, respectively). 
However, at all timepoints, 111In-DOTA-E-[c(RGDfK)]2 blood levels were slightly higher than 
86Y- DOTA-E-[c(RGDfK)]2.     
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Figure 1. Sequential gamma camera images (top) and PET camera images (bottom) of 
the same dog. 
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Figure 2. Time-activity curves of 111In-DOTA-E-[c(RGDfK)]2 and 86Y-DOTA-E-[c(RGDfK)]2. 
 
 
Dose (mGy/MBq)  (mean ± sd)  
Organ 
111In- DOTA-E-[c(RGDfK)]2 86Y- DOTA-E-[c(RGDfK)]2 
Kidney 1.45 ± 0.46 1.13 ± 0.24 
Bladder 1.52 ± 0.06 1.59 ± 0.06 
Liver 0.75 ± 0.11 0.65 ± 0.11 
Spleen 0.83 ± 0.18 1.10 ± 0.19 
Lung * 0.59 ± 0.15 0.30 ± 0.06 
Bone marrow 
(vertebral column ROI) 
0.68 ± 0.32 0.51 ± 0.09 
Bone marrow 
(shoulder ROI) 
0.38 ± 0.10 0.45 ± 0.05 
Bone marrow 
(Shen method) 
0.11 ± 0.02 0.10 ± 0.01 
Effective dose  (mSv/MBq) 0.36 ± 0.05 0.32 ± 0.03 
 
Table 1. 90Y-DOTA-E-[c(RGDfK)]2 radiation doses to the relevant organs as determined by 
MIRDOSE3 after injection of 111In-DOTA-E-[c(RGDfK)]2 and 86Y-DOTA-E-[c(RGDfK)]2 (* = 
dose estimates significantly different; mGy = milligray; ROI = region of interest; mSv = 
millisievert). 
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Dosimetric Analysis 
The radiation doses based on the 111In-DOTA-E-[c(RGDfK)]2 and 86Y-DOTA-E-[c(RGDfK)]2 
images are listed in table 1. Doses to relevant organs were similar, except the lungs. The 
mean dose to the lungs was twice as high when calculated from the 111In-DOTA-E-
[c(RGDfK)]2 images as compared to the 86Y-DOTA-E-[c(RGDfK)]2 images (P < 0.05). 
 
 
Discussion 
 
The present study shows that analysis of 111In-labeled RGD-peptide imaging can be used 
to predict the dosimetry of the 90Y-labeled peptide. Therefore conjugate view gamma 
camera imaging using 111In suffices while 90Y-based dosimetry would require positron-
emitting, cyclotron-produced 86Y and the availability of PET. 111In-DOTA-E-[c(RGDfK)]2 
resulted in identical dynamic distribution in all organs as compared to 86Y-DOTA-E-
[c(RGDfK)]2 with the exception of the lungs. The latter may be due to differences in the 
attenuation correction algorithm for single photon imaging (undercorrection) and PET 
(overcorrection). As doses to the lungs are higher when derived from the 111In-labeled 
compound, future use of 111In-DOTA-E-[c(RGDfK)]2 would not underestimate radiation 
dose to the lungs. 
Our dosimetric analysis showed that the radiation dose to the kidneys of the 90Y-labeled 
peptide is relatively low. This suggests that, unlike for 90Y-labeled octreotide analogues, 
the kidney may not be the dose limiting organ in PRRT with 90Y-DOTA-E-[c(RGDfK)]2.5 
Blood pharmacokinetics of 111In-DOTA-E-[c(RGDfK)]2 and 86Y-DOTA-E-[c(RGDfK)]2 were 
identical after injection in the dogs. However, bone marrow dosimetry based on blood 
kinetics underestimated the radiation dose to the red marrow as the images showed 
bone marrow targeting. This is exemplified by the significantly higher bone marrow uptake 
when based on ROI analysis as compared to the Shen-method. 
We concluded that although no complete match of the 111In and 86Y-labeled peptide 
biodistribution was found, this study showed that the dosimetry of a 90Y-labeled RGD-
peptide can be predicted by conventional analysis of the 111In-labeled surrogate without 
the risk of underestimating organ doses. 
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Chapter 5 
ABSTRACT 
 
The αvβ3 integrin, a transmembrane heterodimeric protein expressed on sprouting 
endothelial cells, binds to the arginine-glycine-aspartic acid (RGD) amino acid sequence 
of extracellular matrix proteins such as vitronectin. Growing malignant tumors 
continuously require angiogenesis. As a result αvβ3 is preferentially expressed in growing 
tumors and a potential target for radiolabeled RGD-peptides. 
In this study we compared the tumor targeting characteristics of a monomeric 
radiolabeled RGD-peptide with those of a dimeric analogue. Both peptides were 
radiolabeled with 99mTc via the hydrazinonicotinamid (=HYNIC) moiety to form 99mTc-
HYNIC-c(RGDfK) and 99mTc-HYNIC-E-[c(RGDfK)]2. In vitro, the IC50 showed a 10-fold higher 
affinity of the dimer for the αvβ3 integrin as compared to the monomer (0.1 vs 1.0 nM). In 
athymic female BALB/c mice with subcutaneously growing OVCAR-3 ovarian carcinoma 
xenografts, tumor uptake peaked at 5.8 ± 0.7 %ID/g and 5.2 ± 0.6 %ID/g for the dimer 
and the monomer, respectively. At 1, 2 and 4 h postinjection (p.i.) uptake of the dimer in 
the tumor was significantly higher than that of the monomeric analogue. Tumor-to-blood 
ratios were highest at 24 h p.i. at a value of 63 for both compounds. At all timepoints 
kidney retention of the dimer was significantly higher as compared to kidney retention of 
the monomer. In conclusion, in this mouse model the dimeric RGD-peptide showed better 
retention in the tumor than the monomeric analogue, most likely due to the bivalent 
interaction with the target cell. Furthermore, kidney retention of the dimeric peptide was 
higher than that of the monomeric peptide.   
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INTRODUCTION 
 
Angiogenesis, the formation of new blood vessels, is a prerequisite for the growth of 
human cancers. It has been shown that angiogenic inhibitors can potentially control 
cancer growth and cancer spread.1 In this study the αvβ3 integrin, a membrane bound 
adhesion molecule expressed on sprouting endothelial cells and not on quiescent 
endothelial cells, is used as a target.2 This integrin can bind to the arginine-glycine-
aspartic acid (RGD) amino acid sequence of extracellular matrix proteins such as 
vitronectin.3,4 Radiolabeled RGD-peptides could specifically target the αvβ3 integrin 
expressed in tumors and could be used for peptide receptor radionuclide imaging (PRRI) 
or peptide receptor radionuclide therapy (PRRT). 
Cyclic RGD-peptides are generally composed of five amino acids.5 Apart from the RGD 
sequence, a variety of two additional amino acids have been used for custom-made 
purposes such as iodination (tyrosine) or linkage of chelators or bridging amino acids (e.g. 
lysine). Commonly used amino acid pairs are phenylalanine-lysine,6 phenylalanine-
tyrosine and tyrosine-valine7 and tyrosine-lysine.7,8 These two amino acids may affect the 
three dimensional structure and the hydrophilicity of the peptide and may thus affect the 
affinity and the in vivo behaviour of the peptide. 
While most cyclic RGD-peptides are monomers, we also synthesized a dimeric RGD-
peptide. Such a dimeric peptide could theoretically bind bivalently and thus more avidly to 
the target cell. This more avid binding of the peptide to the target cell could improve the 
tumor targeting properties. The aim of this study is to compare the in vitro affinities and in 
vivo tumor targeting of the dimeric RGD-peptide to that of its monomeric counterpart. 
 
 
MATERIALS AND METHODS 
 
RGD-peptides 
The peptides used in these studies were synthesized as described previously.6 The cyclic 
pentapeptide RGDfK was conjugated with the chelator hydrazinonicotinamide (HYNIC) via 
the ε-aminogroup of the lysine residue to form HYNIC-c(RGDfK)6 (Fig. 1). The dimer 
constituted of two cyclic pentapeptides, linked via a glutamic acid residue that was 
conjugated with HYNIC, resulting in HYNIC-E-[c(RGDfK)]2. Molecular weights of monomeric 
and dimeric peptide are 840 and 1558 Dalton, respectively. 
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Figure 1.  Structural formula of the 99mTc-labeled, HYNIC-conjugated monomeric and 
dimeric RGD-peptides 99mTc-HYNIC-c(RGDfK) and 99mTc-HYNIC-E-[c(RGDfK)]2 . 
 
 
Immobilized Human Placental αvβ3 Receptor ELISA Assay 
The in vitro binding affinities of the monomeric and dimeric peptide were determined as 
described earlier.6 Vitronectin was purchased from Telios Pharmaceuticals (La Jolla, CA, 
USA) and αvβ3 integrin receptors were purified from placenta as described by Pytela et 
al.9. Briefly, wells were coated with αvβ3 integrin receptors and incubated with a mixture of 
peptide and biotinylated vitronectin ([B]Vn). [B]Vn binding was quantified using goat anti-
biotin alkaline phosphatase conjugated antibody (GAB). Unbound GAB was removed and 
phosphatase activity was developed. The enzyme product was detected 
spectrophotometrically at 405 nm. Three independent measurements were made and 
the IC50 was calculated by fitting the percent inhibition values to a regression line.  
 
Radiolabeling of the RGD-peptides 
Lyophilized coligand kits containing 6.5 mg tricine and 5 mg trisodium 
triphenylphosphine–3-3’-3’’-trisulfonate (TPPTS), 40 mg mannitol and 25 µmol succinate 
buffer, pH 5.0 were produced and stored at -20 °C. To one kit 27 µg HYNIC-E-[c(RGDfK)]2 
(100 µg/ml) or 16 µg HYNIC-c(RGDfK) (100 µg/ml) was added together with 740 MBq 
Na99mTcO4 (ca. 0.3 ml). The reaction mixture was heated at 100 °C for 15 minutes. 
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Colloid content was checked by instant thin layer chromatography (ITLC) on sillicagel ITLC 
strip (Gelman Sciences, Ann Arbor, MI, USA) using 0.9% NaCl as the mobile phase. The 
reaction products were analyzed by reversed-phase HPLC (HP 1100 series, Hewlett 
Packard, Palo Alto, CA, USA) using a C18 column (Zorbax, 4.6 mm × 250 mm) with an in-
line radiodetector (Flo-One Beta series A-100, Radiomatic, Meriden, CT, USA). The column 
was eluted with 0.025 M phosphate buffer, pH 7.0 with a 12 to 15% acetonitrile gradient 
(1.0 ml/min). 
 
Animal Model 
In the right upper flank of 6-8 weeks old female nude BALB/c mice, 0.1 ml of a cell 
suspension of 1.108 cells/ml NIH:OVCAR-3 ovarian carcinoma cells was s.c. injected. Ten 
days later mice were randomly divided into two groups (20 mice/group). One group 
received 1.85 MBq 99mTc-HYNIC-E-[c(RGDfK)]2 (43 pmol/mouse) and the other group 
received 1.85 MBq 99mTc-HYNIC-c(RGDfK) (47 pmol/mouse) via the tail vein. Animals 
were treated in accordance with the protocols approved by the local Animal Wellfare 
Committee. Immunohistochemical staining with the murine monoclonal antibody against 
human αvβ3 (LM609) and subsequent flowcytometric analysis of the NIH:OVCAR-3 cells 
indicated that the cells express the αvβ3 integrin. 
 
 
Biodistribution Studies 
At 0.5, 1, 2, 4 and 24 h p.i. mice were anaesthesized with ether (4 mice per group per 
timepoint). After blood collection from the retro-orbital venous plexus, mice were killed by 
cervical dislocation. Tissues (tumor, muscle, lung, spleen, kidney, liver, small intestine) 
were dissected and weighed. The activity in tissues and in injection standards was 
measured in a shielded well-type scintillation gamma counter (1480 Wizard, Wallac, 
Turku, Finland) and expressed as the percentage of the injected dose per gram tissue 
(%ID/g). Using these data tumor-to-blood ratios and tumor-to-kidney ratios were 
calculated. 
 
Statistical Analysis 
For each of the 8 organs, differences in uptake between the monomeric and the dimeric 
peptide were analyzed using two-way ANOVAs with a level of significance of 0.05. 
Differences in tumor-to-blood ratios and tumor-to-kidney ratios were analyzed using t-
tests at a level of significance of 0.05. 
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RESULTS 
 
Characterization of  the RGD-peptides 
The IC50 of the monomer for the αvβ3 receptor was 1.0 nM whereas the IC50 of the dimer 
was 0.1 nM as determined in the immobilized human placental αvβ3 receptor ELISA 
assay,  indicating a more avid binding of the dimer to αvβ3 as compared to the monomer. 
Both peptides also have affinity for αvβ5, however, their IC50 for αvβ5 is at least 10-fold 
higher. A typical result of HPLC-radiochromatograms of the monomeric peptide and the 
dimeric peptide after radiolabeling is shown in Fig 2. The monomer eluted at 3.9 minutes. 
The elution profile of the dimer showed two equally sized peaks at 16.8 and 20.1 
minutes, representing the two diastereomers of the labeled peptide.6 The preparations 
contained less than 2% colloid according to the ITLC profile, the radiochemical purity of 
each of the radiolabeled peptides exceeded 95%. 
 
 
 
 
 
 
 
 
99mTc-HYNIC-E-[c(RGDfK)]2 99mTc-HYNIC-c(RGDfK)   
 
Figure 2. RP-HPLC profiles of 99mTc-HYNIC-c(RGDfK) and 99mTc-HYNIC-E-[c(RGDfK)]2 
showing a radiochemical purity exceeding 90% of both radiolabeled peptides. Note the 
two peak elution pattern of 99mTc-HYNIC-E-[c(RGDfK)]2 reflecting the two stereoisomers of 
this compound. 
 
  
The αvβ3 binding capacity of the radiolabeled peptides was confirmed in an in vitro cell 
binding assay. Human ovarian carcinoma IGROV-1 cells were trypsinized and 
preincubated in Tris-HCl, pH 7.4 supplemented with 1 mM MgCl2, 1 mM CaCl2 and 1 mM 
MnCl2 for 15 min at 0 °C. A fixed amount of radiolabeled peptide (105 cpm) was 
incubated with increasing cell concentrations (1.2 x 107 - 2 x 108 cells/ml, 0.5 ml per 
incubation) in RPMI medium (Gibco BRL Life Technologies, Breda, The Netherlands) 
supplemented with 0.5 % bovine serum albumin and 0.05 % NaN3. Nonspecific binding 
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was determined by coincubating an excess of unlabeled peptide. The receptor binding 
fraction of the radiolabeled peptides at infinite cell concentration as derived from the 
modified Line-weaver Burke plot, exceeded 70%. 
 
Biodistribution Studies 
The results of the biodistribution studies are summarized in Fig. 3. The weight of the 
dissected tumors ranged from 0.04 to 0.4 g. Both the monomeric and the dimeric 
peptide cleared rapidly from the blood. Blood levels of the dimeric peptide were slightly 
higher at 1, 2 and 4 h p.i.. Tumor uptake of the dimer was maximal at 5.8 ± 0.7 %ID/g at 
1 h p.i. while tumor uptake of the monomer peaked at 5.2 ± 0.6 %ID/g at 30 min p.i.. At 
1, 2 and 4 h p.i. the uptake of the dimer in the tumor was significantly higher as 
compared to the uptake of the monomer. Tumor-to-blood ratios of both compounds 
increased over time and were equal at 24 h p.i. (63 ± 6 and 63 ± 7, respectively (Fig. 4, 
top)). 
The kidneys were the organs with the highest uptake. The kidney uptake of the dimeric 
peptide was significantly higher than the kidney uptake of the monomeric peptide at all 
time points, consequently tumor-to-kidney ratios of the monomeric peptide were higher 
than the tumor-to-kidney ratios of the dimeric peptide (Fig. 4, bottom). 
Both peptides showed uptake in spleen, liver and lungs. Slight but significant differences 
in uptake between the monomer and the dimer were observed in muscle and lung at two 
time points. The uptake of the dimeric peptide and the monomeric peptide was not 
statistically different in spleen, liver and intestine. 
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Figure 3. Biodistribution of the monomeric 99mTc-HYNIC-c(RGDfK) peptide (top) and the 
dimeric 99mTc-HYNIC-E-[c(RGDfK)]2 peptide (bottom) in athymic mice with a s.c. OVCAR-3 
tumors. (×: Statistically significant difference of the organ uptakes of the dimeric peptide 
as compared to the monomeric peptide). 
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Figure 4. Tumor-to-blood ratios (top) and tumor-to-kidney ratios (bottom) of monomeric 
99mTc-HYNIC-c(RGDfK) peptide and dimeric 99mTc-HYNIC-E-[c(RGDfK)]2 peptide in athymic 
mice with a s.c. OVCAR-3 tumors. 
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DISCUSSION 
 
In this study the in vivo characteristics of a monomeric and a dimeric form of an αvβ3 
integrin binding RGD-peptide were compared in a mouse tumor model. Both RGD-
peptides had a high affinity for the αvβ3 integrin as demonstrated in an ELISA; the 
integrin-affinity of the dimer was tenfold higher as compared to that of the monomer. 
Presumably, due to its bivalent interaction with αvβ3, the dimer binds more avidly to the 
αvβ3 integrin. Similarly, in a recent study Kok et al. demonstrated enhanced affinity of 
proteins substituted with multiple RGD-sequences for αvβ3-expressing cells as compared 
to the monomeric RGD-peptides.10  
In our study tumor targeting of a monomeric and a dimeric radiolabeled RGD-peptide was 
evaluated in athymic mice with s.c. OVCAR-3 tumors. In this model both peptides showed 
good accumulation in the αvβ3 expressing tumor. Uptake in the tumor and tumor-to-blood 
ratios were at least twice as high as the values reported for the radiolabeled cyclic RGD-
peptide described by Haubner et al.11  Tumor uptake of the dimeric peptide between 1 
and 4 h p.i. was higher than that of the monomeric peptide. However, at 24 h p.i. tumor 
uptake of the peptides was not different. This suggests that in line with the in vitro affinity 
results the dimeric peptide exhibits more avid binding to the αvβ3 integrin expressing cells 
than the monomeric peptide.   
A prominent difference between the two peptides was the difference in renal handling: 
the dimer showed prolonged retention in the kidneys. In general, peptides with a 
molecular weight <60 kDa are rapidly cleared to the primary urine by glomerular filtration, 
followed by subsequent reabsorbtion in the proximal tubular cells. In the proximal tubular 
cells these peptides are subsequently internalized and degraded in the lysosomes.12 
Following this pathway the main radiolabeled catabolite  of the monomeric RGD-peptide 
will probably be 99mTc-HYNIC-lysine, while that of the dimeric peptide will probably be 
99mTc-HYNIC-glutamic acid. Both compounds will be retained in the lysosomes. The 
difference in tubular reabsorption between the dimer and the monomer could be due to 
their difference in charge: In general positively charged peptides are more efficiently 
reabsorbed in the negatively charged proximal renal tubular cells.12 The dimeric peptide 
is more positively charged due to the presence of the secondary amino groups. 
An important application of RGD-peptides in oncology could be PRRT. For peptide 
radionuclide therapy, absolute tumor uptake is an important criterium. However, as the 
kidney may be the dose-limiting organ, low kidney retention is also very important.13 The 
monomeric peptide shows relatively good tumor retention with relatively low uptake in the 
kidneys. If in the therapeutic setting, the RGD-peptides labeled with a cytotoxic 
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radionuclide would be administered at maximal tolerable radiation dose to the kidney, 
the use of the monomeric peptide would cause a higher radiation dose to the tumor. Co-
infusion of positively charged amino acids that temporarily block endocytosis by the 
proximal tubular cells could reduce kidney uptake of the radiolabeled peptides.12 The use 
of this preventive infusion could increase the therapeutic window for both peptides. 
Alternatively, reduction of the positive charge of the peptide could also reduce their 
uptake in the kidneys. 
 
In conclusion, this study showed enhanced retention in the tumor of a radiolabeled 
dimeric RGD-peptide compared to its monomeric counterpart, indicating enhanced 
targeting of the dimer to the αvβ3-expressing tumor. However, as the monomeric peptide 
showed a higher tumor-to-kidney ratio, this analogue could be superior in PRRT. Future 
studies will have to demonstrate whether radiolabeled RGD-peptides have a therapeutic 
potential. 
 
 
ACKNOWLEDGMENTS 
 
The authors thank G. Grutters and H. Eikholt (Central Animal Facility) for professional 
animal care. 
 
 
REFERENCES 
 
1. Folkman J. Tumor angiogenesis. Adv.Cancer Res. 1985; 43:175-203 
2. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. 
Science 1994; 264:569-71 
3. Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated 
by small synthetic fragments of the molecule. Nature 1984; 309:30-3 
4. Smith JW, Cheresh DA. The Arg-Gly-Asp binding domain of the vitronectin receptor. 
Photoaffinity cross-linking implicates amino acid residues 61-203 of the beta subunit. 
J.Biol.Chem. 1988; 263:18726-31 
5. Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, Jonczyk A, Goodman SL, 
Kessler H. N-Methylated cyclic RGD-peptides as highly active and selective αvβ3  integrin 
antagonists. J.Med.Chem. 1999; 42:3033-40 
 77
Chapter 5 
6. Liu S, Edwards DS, Ziegler MC, Harris AR, Hemingway SJ, Barrett JA. 99mTc-labeling of a 
hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging 
tumors. Bioconjug.Chem. 2001; 12: 624-9 
7. Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, 
Stocklin G, Schwaiger M. Radiolabeled αvβ3 integrin antagonists: A new class of tracers for 
tumor targeting. J.Nucl.Med. 1999; 40: 1061-71 
8. Van Hagen PM, Breeman WA, Bernard HF, Schaar M, Mooij CM, Srinivasan A, Schmidt MA, 
Krenning EP, de Jong M. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for 
tumour imaging and radionuclide therapy. Int.J.Cancer 2000; 90: 186-98 
9. Pytela R, Pierschbacher MD, Argraves S, Suzuki S, Ruoslahti E. Arginine-glycine-aspartic 
acid adhesion receptors. Methods Enzymol. 1987; 144: 475-89 
10. Kok RJ, Schraa AJ, Bos EJ, Moorlag HE, Asgeirsdottir SA, Everts M, Meijer DK, Molema G. 
Preparation and functional evaluation of RGD-modified proteins as αvβ3 integrin directed 
therapeutics. Bioconjug.Chem. 2002; 13: 128-35 
11. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, 
Kessler H, Schwaiger M. Glycosylated RGD-containing peptides: tracer for tumor targeting 
and angiogenesis imaging with improved biokinetics. J.Nucl.Med. 2001; 42: 326-36 
12. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody 
fragments and peptides for diagnosis and therapy: present status, future prospects and 
limitations. Eur.J.Nucl.Med. 1998; 25: 201-12 
13. Boerman OC, Oyen WJ, Corstens FH. Between the Scylla and Charybdis of peptide 
radionuclide therapy: hitting the tumor and saving the kidney. Eur.J.Nucl.Med. 2001; 28: 
1447-9 
 78 
 
  
CHAPTER 6 
 
 
 
IMPROVED TUMOR TARGETING OF RADIOLABELED 
 
RGD-PEPTIDES USING RAPID DOSE FRACTIONATION 
 
 
 
 
Marcel Janssen 
Cathelijne Frielink 
Ingrid Dijkgraaf 
Wim Oyen 
D. Scott Edwards 
Milind Rajopadhye 
Leon Massuger 
Frans Corstens 
Otto Boerman 
 
 
Department of Nuclear Medicine and Obstetrics and Gynecology, 
University Medical Center Nijmegen, Nijmegen, the Netherlands; 
Bristol-Myers Squibb Medical Imaging, Billerica, MA, USA 
 
 
 
 
 
 
 
 
Submitted 
 
Chapter 6 
Abstract 
 
Arginine-glycine-aspartic acid (RGD) peptides preferentially bind to αvβ3 integrin, an 
integrin expressed on newly formed endothelial cells involved in the process of 
angiogenesis and on various tumor cells. When labeled with β-emitting radionuclides, 
these peptides could be used for peptide receptor radionuclide therapy of malignant 
tumors. Even at maximal specific activity, a therapeutic dose of 90Y-labeled RGD-peptide 
would require a peptide dose that could saturate αvβ3 targets. These studies aimed to 
investigate whether tumor targeting could be optimized by dose fractionation. 
The RGD-peptide E-[c(RGDfK)]2 was labeled with 111In for biodistribution experiments and 
with 90Y for therapy experiments via the 1,4,7,10-tetraazadodecane-N,N’,N’’,N’’’-
tetraacetic acid (DOTA) moiety. Using mice with NIH:OVCAR-3 ovarian carcinoma 
xenografts, optimal tumor uptake was obtained at peptide doses up to 1 µg (4.9 %ID/g). 
A peptide dose of 5 µg, needed to reach the maximum tolerable dose (MTD) in the 
therapeutic setting, was administered as 5 portions of 1 µg. Tumor uptake of the fifth 
portion was significantly higher than that of the single 5 µg portion (3.3 %ID/g vs. 2.1 
%ID/g). The therapeutic efficacy of 37 MBq 90Y-DOTA-E-[c(RGDfK)]2 (1 x 5 µg) was 
compared with that of 37 MBq administered in five equal portions (5 x 1 µg). No 
difference in tumor growth between the fractionated and the non-fractionated therapy 
was observed. 
In conclusion, optimal tumor targeting of DOTA-E-[c(RGDfK)]2 in this model is achieved at 
a peptide dose of 1 µg. Higher radiation doses were guided to the tumor by dose 
fractionation. However, therapeutic efficacy of the radiolabeled peptide was not 
significantly improved by dose fractionation. 
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Introduction 
 
Integrins are a group of adhesion molecules consisting of two non-covalently bound 
transmembranous subunits (α and β). Integrin αvβ3 mediates cellular adhesion to 
extracellular matrix proteins (e.g. vitronectin, fibrinogen, laminin, collagen) through 
exposed tripeptide arginine-glycine-aspartic acid (RGD) amino acid moieties.1 Integrin 
αvβ3 is preferentially expressed on proliferating endothelial cells.2 For their growth beyond 
a certain size tumors are dependent on the formation of new blood vessels from pre-
existing capillaries (angiogenesis).3-5 In addition, αvβ3 is expressed on various tumor cell 
types (ovarian cancer, neuroblastoma, breast cancer, melanoma, a.o.). Due to the 
restricted expression of αvβ3 in tumors, αvβ3 is considered a suitable membrane structure 
for tumor targeting.6  
The potential of αvβ3-binding peptides to serve as vehicles for targeting tumors with 
radionuclides has been investigated by several groups. Haubner et al. studied two 
radioiodinated cyclic pentapeptides (c(RGDyV) and c(RGDfY); IC50 = 2 nM) in nude mice with 
various tumors.7 Tumor uptake peaked 10 minutes after injection (3.50±0.73 %ID/g). Both 
peptides mainly cleared via the hepatobiliary route. Subsequently, they synthesized a 
glycosylated version of c(RGDyK) that cleared predominantly via the kidneys.8 This 
compound (IC50 = 40 nM) had a longer circulatory half-life and a significantly reduced 
uptake in the liver (2 vs. 10 %ID/g at 1 h post-injection (p.i.)). Most importantly, the 
glycosylated RGD-peptide had a clearly higher uptake in the tumor (3.0±0.31 %ID/g vs. 
0.92±0.16 %ID/g at 4 h p.i.). Van Hagen et al. studied the cyclic peptide c(RGDyK) 
conjugated with DTPA.9 Uptake of the 111In-labeled peptide in CA20948 pancreatic tumors 
in rats amounted to 0.2 %ID/g at 24 h p.i., while at this timepoint the peptide was almost 
completely cleared from the blood (0.003 %ID/g). 
In our previous studies we have shown that the radiolabeled c(RGDfK)-peptides 
specifically accumulated in αvβ3-positive ovarian cancer xenografts in athymic mice.10 
The dimeric RGD-peptide was better retained in the tumor than the monomeric RGD-
peptide.11 The uptake of 111In-DOTA-E-[c(RGDfK)]2 in s.c. OVCAR-3 tumors peaked at 7.5 
%ID/g 2 h after intravenous injection. A single injection of this peptide labeled with 90Y 
(37 MBq/mouse) caused a significant growth delay of the tumors. In the present study, 
the optimal peptide dose for peptide radionuclide therapy with the dimeric RGD-peptides 
was determined. In addition, the effect of rapid dose fractionation on the radiation dose 
guided to the tumors and on the therapeutic efficacy was studied. 
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Material and methods 
 
Radiolabeling of the RGD-peptide 
The synthesis and characterization of the dimeric cyclic RGD-peptide E-[c(RGDfK)]2 
conjugated with the chelator 1,4,7,10-tetraazadodecane-N,N’,N’’,N’’’-tetraacetic acid 
(DOTA) was described previously.10,12,13 The peptide has a high affinity for the αvβ3 
integrin (IC50 = 0.9 nM). DOTA-E-[c(RGDfK)]2 was radiolabeled with 111In to obtain 111In-
DOTA-E-[c(RGDfK)]2. Briefly, 250 µg DOTA-E-[c(RGDfK)]2 was dissolved in 4.5 ml 0.25 M 
ammoniumacetate buffer, pH 7.0 and 160 MBq 111InCl3 (Mallinckrodt, Petten, The 
Netherlands) was added. The mixture was heated for 15 min at 100 °C. The 
radiochemical purity was determined by reversed-phase high-performance liquid 
chromatography (RP-HPLC) (HP 1100 series, Hewlett Packard, Palo Alto, CA, USA) using a 
C18 column (RX-C18, 4.6 x 250 mm, Zorbax) eluted with an isocratic eluent (13% 
acetonitrile in 25 mM phosphate buffer, pH 6.0) at 1.0 ml/min. The radioactivity of the 
eluate was monitored using an in-line radiodetector (Flo-One Beta series, Radiomatic, 
Meriden, CT, USA). 
90Y-DOTA-E-[c(RGDfK)]2 was prepared by adding 2775 MBq 90YCl3 (Perkin Elmer, Boston, 
MA, USA) to 375 µg DOTA-E-[c(RGDfK)]2 dissolved in 1.75 ml 0.25 M ammoniumacetate 
buffer, pH 7.0. The mixture was heated at 100 °C for 15 min. Quality control was carried 
out as described for the 111In-labeled peptide. The scrambled sequence control peptide 
DOTA-E-[c(RGKfD)]2 served as a control in the therapy experiments and was radiolabeled 
with 90YCl3 analogously.  
 
Animal Model 
In our animal model, 0.2 ml of a cell suspension of NIH:OVCAR-3 human ovarian 
carcinoma cells (5 x 107 cells/ml) was injected subcutaneously (s.c.) in the right flank of 
6-8 weeks old female nude BALB/c mice. Two weeks after inoculation of the tumor cells, 
when the diameter of the tumor was 6-8 mm, mice were i.v. injected with the radiolabeled 
peptides via the tail vein. 
 
Biodistribution Studies 
In this experiment the effect of the peptide dose escalation  and the effect of peptide 
dose fractionation was studied. Five groups of five mice received 0.5, 1.0, 2.0, 5 or 10 µg 
of the DOTA-E-[c(RGDfK)]2 peptide labeled with 0.4 MBq 111In (dose escalation). The 
effect of dose fractionation on the biodistribution of 111In-DOTA-E-[c(RGDfK)]2 was studied 
in two additional groups of five mice that received five injections: four injections with 1 µg 
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nonradioactive DOTA-E-[c(RGDfK)]2 were followed with a injection 1 µg DOTA-E-
[c(RGDfK)]2 labeled with 0.4 MBq 111In. These two groups varied in the time interval 
between the five injections (time interval of 1 h and 2 h). Two hours after injection of the 
radiolabeled peptide all mice were euthanized with CO2/O2. Blood was collected by 
cardiac puncture and tissues (tumor, muscle, lung, spleen, kidney, liver, small intestine) 
were dissected and weighed. The activity in tissues and injection standards was 
measured in a shielded well-type scintillation gamma counter (1480 Wizard, Wallac Oy, 
Turku, Finland) and expressed as %ID/g. 
 
Peptide Receptor Radionuclide Therapy 
The therapeutic efficacy of 37 MBq 90Y-DOTA-E-[c(RGDfK)]2 (5 µg) administered as one 
bolus injection was compared with the therapeutic efficacy of the same dose of 90Y-DOTA-
E-[c(RGDfK)]2 administered in five equal portions. Four groups of 10 mice with s.c. 
NIH:OVCAR-3 tumors were used in this experiment (Group A-D). Group A received 37 MBq 
90Y-DOTA-E-[c(RGDfK)]2 (peptide dose: 5 µg) as a single bolus injection (0.2 ml). Group B 
received the same dose of 90Y-DOTA-E-[c(RGDfK)]2 administered in 5 equal portions (5 x 
7.4 MBq; 5 x 1 µg) with a 1 h interval between the five injections. Mice in group C 
received 5 equal doses of the scrambled sequence control peptide 90Y-DOTA-E-
[c(RGKfD)]2 (5 x 7.4 MBq, 5 x 1 µg, 1 h interval). Mice in group D received 5 subsequent 
injections with nonradioactive DOTA-E-[c(RGKfD)]2 peptide (5 x 1 µg, 1 h interval) and also 
served as control group.  
The size of the tumors was measured twice weekly in 3 dimensions using a caliper. The 
volume was estimated assuming the tumors were elipsoids, using the formula: volume = 
4/3π × ½.length × ½.width × ½.height. At the time of the injection the volume of the s.c. 
tumors ranged from 27 to 150 mm3. When the volume of the tumor exceeded 2 cm3, 
mice were taken out of the experiment and euthanized. 
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 3.0 (GraphPad Software, San 
Diego, CA, USA). The biodistribution data were analyzed using the one-way ANOVA test. 
The level of significance was set at p=0.05. If p < 0.05 Tukey-Kramer multiple 
comparisons post tests were performed. 
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Results 
 
Radiolabeled Peptides 
RP-HPLC analysis indicated that the radiochemical purity of DOTA-E-[c(RGDfK)]2 labeled 
with 111In and 90Y was 96 % and 95 %, respectively. The αvβ3 binding capacity of the 
111In-labeled peptide was confirmed  in an in vitro cell binding assay on IGROV-1 human 
ovarian carcinoma cells as described previously.10 
 
Biodistribution studies 
The biodistribution of 111In-DOTA-E-[c(RGDfK)]2 in athymic mice with s.c. OVCAR-3 tumors 
at a peptide dose of 1 µg per mouse is shown in Fig. 1. Two hours after injection, the 
highest activity concentration was found in the tumor: 4.8 ± 0.7 %ID/g. The 111In-labeled 
peptide cleared very rapidly from the blood (0.08 %ID/g, 2 h p.i.), and consequently the 
tumor-to-blood ratio in these mice was relatively high (63 ± 5).  
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Figure 1. Biodistribution of 111In- DOTA-E-[c(RGDfK)]2 peptide in athymice mice with s.c. 
OVCAR-3 tumors 2 h after injection at a peptide dose of 1 µg. 
 
 
The effect of the peptide dose on the biodistribution of 111In-DOTA-E-[c(RGDfK)]2 is shown 
in Table 1. Highest uptake in the tumor was found at  a peptide dose of 0.5 and 1.0 µg 
(4.87 ± 0.60 %ID/g and 4.73 ± 0.65 %ID/g, p>0.05) (Fig 2). Uptake at a peptide dose of 
2, 5 and 10 µg (3.20 ± 0.26 %ID/g, 2.07 ± 0.46 %ID/g, 1.54 ± 0.15 %ID/g, respectively) 
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was significantly lower (p < 0.01), most likely due to saturation of accessible αvβ3 integrin 
expressed in the tumor. The uptake of 111In-DOTA-E-[c(RGDfK)]2 in the normal tissues 
(muscle, lung, liver, spleen and intestine) also was reduced at the higher peptide doses, 
suggesting that the localisation of the peptide in these normal tissues was receptor 
mediated and saturable (Table 1). 
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Figure 2. Tumor uptake of 111In-DOTA-E-[c(RGDfK)]2 peptide in athymice mice with s.c. 
OVCAR-3 tumors 2 h after injection at various peptide doses. Note that optimal tumor 
uptake is obtained with a peptide dose of 0.5 and 1.0 µg. At higher peptide doses the 
uptake in the tumor is lower due to saturation of the αvβ3 binding sites in the tumor. In 
addition, the uptake in the tumor of the fifth fraction of five 1-µg doses of DOTA-E-
[c(RGDfK)]2 (with 1- or 2-h time interval) is shown. 
 
 
Interestingly, fractionating the 5 µg peptide dose in 5 fractions of 1 µg each, the uptake in 
tumor of the last 1 µg dose was higher than that of the 5 µg dose bolus injection (3.18 ± 
0.56 %ID/g vs. 2.07 ± 0.46 %ID/g, p < 0.05). Still, the tumor uptake of the last fraction of 
the fractionated dose was significantly lower than that of a single dose of 1 µg (3.18 ± 
0.56 %ID/g vs. 4.73 ± 0.65 %ID/g, p < 0.01). The uptake of the fractionated dose was 
not affected by the time interval between the injections (1 h or 2 h, p > 0.05).  
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       Dose 
Organ 
0.5 µg
 
1.0 µg
 
2.0 µg 
 
5.0 µg
 
10 µg
 
5×1.0 µg 
(1 h) 
5×1.0 µg 
(2 h) 
Blood 0.12±0.02 0.08±0.01 0.08±0.01 0.06±0.01 0.06±0.01 0.05±0.01 0.05±0.01 
Muscle 0.42±0.02 0.28±0.03 0.27±0.07 0.13±0.01 0.16±0.08 0.29±0.11 0.28±0.06 
Tumor 4.87±0.60 4.73±0.65 3.20±0.26 2.07±0.46 1.54±0.15 3.28±0.60 3.18±0.56 
Lung 0.97±0.07 1.11±0.09 0.72±0.08 0.47±0.09 0.44±0.06 0.70±0.10 0.64±0.01 
Spleen 2.03±0.08 1.99±0.11 1.50±0.20 1.14±0.15 0.79±0.03 1.58±0.12 1.23±0.10 
Kidney 2.91±0.11 2.93±0.28 2.37±0.36 2.04±0.18 2.26±0.12 2.08±0.14 1.93±0.25 
Liver 2.18±0.08 2.03±0.26 1.55±0.24 0.93±0.10 0.70±0.08 1.50±0.19 1.17±0.14 
Intestine 3.46±0.37 3.08±0.92 2.51±0.39 1.61±0.30 1.06±0.14 2.25±0.30 1.93+0.29 
 
Table 1. Biodistribution (%ID/g±SD) of 111In- DOTA-E-[c(RGDfK)]2 at various peptide doses 
in athymice mice with s.c. OVCAR-3 tumors 2 h after injection. In the two groups of mice 
that received a fractionated dose (5 x 1 µg), the biodistribution of the fifth fraction of the 
dose is shown. 
 
 
Peptide Receptor Radionuclide Therapy 
The MTD of 90Y-DOTA-E-[c(RGDfK)]2 in this mouse model is 37 MBq per mouse as 
determined previously. The maximum specific activity of 90Y-labeled DOTA-E-[c(RGDfK)]2 
is 7.4 MBq/µg. Therefore, the MTD of the peptide has to be administered with a peptide 
dose of at least 5 µg. The biodistribution experiments indicated that 5 µg of peptide can 
be targeted more efficiently to the OVCAR-3 tumor in this mouse model when 
administered as a fractionated dose (5 x 1 µg). Therefore, the therapeutic efficacy of a 
single bolus injection of 37 MBq 90Y-labeled DOTA-E-[c(RGDfK)]2 was compared with that 
of the same activity dose administered as five subsequent injections with a 1 h time 
interval in a peptide receptor radionuclide therapy experiment (Fig. 3).  
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Figure 3. Growth curves of the s.c. OVCAR-3 tumors in the four groups of mice (7-10 
mice/group) after i.v. injection of 37 MBq 90Y-DOTA-E-[c(RGDfK)]2 (5 µg) (○), 5x7.4 MBq 
90Y-DOTA-E-[c(RGDfK)]2 (5x1 µg) (●), 5x7.4 MBq control peptide 90Y- DOTA-E-[c(RGKfK)]2 
(5 x 1 µg) (■) or nonradioactive  DOTA-E-[c(RGDfK)]2 (5 x 1 µg) (□). 
 
 
Dose fractionation of the activity dose of 37 MBq of 90Y- DOTA-E-[c(RGDfK)]2 in five equal 
portion did not improve the growth inhibitory effect of the radionuclide therapy when 
compared to therapy with 37 MBq of 90Y- DOTA-E-[c(RGDfK)]2 administered in one 
injection of 5 µg of peptide. The growth rate of the tumors in both these groups was 
significantly delayed as compared to the growth of the tumors in the mice that received 
90Y-labeled scrambled control peptide or non-radioactive peptide. 
 
 
Discussion 
 
The present study aimed to optimize peptide receptor radionuclide therapy with a 90Y-
labeled dimeric cyclic RGD-peptide using rapid dose fractionation. The maximum specific 
activity of the 90Y-labeled DOTA-E-[c(RGDfK)]2 peptide that we use for peptide receptor 
radionuclide therapy is 7.4 MBq/µg, while a total activity dose of 37 MBq can be 
administered safely to the mice. Therefore, a therapeutic dose contains at least 5 µg of 
the DOTA-E-[c(RGDfK)]2 peptide. However, the peptide dose escalation study indicated 
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that at peptide doses exceeding 1 µg/mouse the uptake in the tumor decreases, most 
likely due to saturation of the αvβ3 binding sites in the tumor. Similarly, the uptake in 
most normal tissues tested (lung, spleen, kidney, liver and intestine) was significantly 
lower at the higher peptide doses. This observation was in line with earlier studies in 
which we showed that part of the uptake of the peptide in normal tissues can be blocked 
with an excess of cold peptide10, indicating that the uptake in these tissues is saturable. 
Whether this is due to expression of αvβ3 integrin in these tissues remains to be 
investigated. 
When the 5-µg dose was administered in five equal portions with a one or two hour time 
interval, the uptake in the tumor of the last 1 µg portion (3.2 ± 0.2 %ID/g) was 
significantly higher than that of the 5 µg dose injected as a bolus (2.1 ± 0.5 %ID/g). 
These data indicate that the uptake of the 5 x 1 µg dose was even higher, because the 
uptake of the first 1 µg fraction in the tumor is 4.7 ± 0.6 %ID/g. These results indicate 
that the mean uptake of the 5 x 1 µg dose is approximately 4.0 %ID/g, being the mean 
tumor uptake of the first and the fifth dose. Thus, the biodistribution study showed that 
rapid dose fractionation can increase the uptake of the radiolabeled peptide almost two-
fold. These data suggest that within one hour after targeting the αvβ3 binding sites in the 
tumor with the RGD-peptide, at least part of the αvβ3 binding sites become available 
again for binding newly administered RGD-peptide, either due to reexpression or due to 
release of the RGD-peptide from the receptor. 
Despite the fact that tumor uptake of the radiolabeled peptide improved when the 
fractionated dose scheme was applied, the therapeutic effect of 37 MBq 90Y-DOTA-E-
[c(RGDfK)]2 was not increased significantly when administered as 5 equal fractions of 7.4 
MBq. This could be due to the fact that the therapeutic effect of 90Y-DOTA-E-[c(RGDfK)]2 
administered as a single bolus was considerable. 
Various studies have investigated the potential of dose fractionation in radionuclide 
therapy. The rationale and design of these studies varied largely. Several studies aimed 
to overcome heterogeneity of intratumoral distribution of the radionuclide and the 
consequent nonuniformity of tumor radiation doses.14,15 Other studies aimed to reduce 
marrow toxicity and thereby to increase the total radioactivity dose that can be 
administered.16,17 Only a few studies compared the tumor dosimetry and/or therapeutic 
effect of the same activity dose administered either as a single injection or as multiple 
injections. In mice with HeLa xenografts the tumor targeting with 22 MBq 125I-labeled 
anticytokeratin monoclonal antibody administered as one, three or ten injections was 
investigated.18 In contrast with our findings, these investigators found reduced uptake in 
the tumors when the dose was administered in multiple injections. However, in that study 
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the time interval between the injections was much longer and the antibody protein dose 
did not saturate the target antigen in the tumor. Goel et al. described a study in mice with 
LS-174T tumors in which they compared the therapeutic efficacy of an activity dose of 37 
MBq 131I-labeled CC49 antibody construct either as a single bolus or as 4 injections (4 x 
0.25 MBq) with a 1-day time interval.19 They found that the therapeutic efficacy of the 
fractionated dose was significantly higher than that of the single injection. 
In conclusion, the present study shows that rapid dose fractionation can improve the 
targeting of αvβ3-expressing tumors with radiolabeled dimeric cyclic RGD-peptide. Our 
studies suggest that one hour after targeting the αvβ3 binding sites in the tumor with the 
RGD-peptide, new αvβ3 binding sites are available again for binding RGD-peptides. 
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GENERAL DISCUSSION AND FUTURE PROSPECTS 
 
Chapter 7 
General discussion and future prospects 
 
After cancer of the breast, lung and large bowel, ovarian cancer is the fourth most 
common cause of cancer death among women in the western world. Ovarian cancer has 
a peak incidence between 50 and 70 years of age. In most cases, peritoneal 
dissemination is already present at detection. The current standard therapy for this stage 
of disease is debulking surgery followed by multidrug chemotherapy. This intensive 
treatment regimen results in a 5-year survival of a mere 20-30 % for advanced stage 
disease. These unfavorable features require the development for new treatment 
strategies or treatment modalities. 
 
 
Radiolabeled antibodies 
 
Monoclonal antibodies binding to epitopes on cancer cells are attractive vehicles for the 
treatment of malignant diseases. Although some monoclonal antibodies have intrinsic 
anti-tumor effects, antibodies can be used as carriers for anti-cancer drugs and 
radionuclides. Although the antibody-antigen concept has been applied in oncology for 
more than 25 years, only recently the first radiolabeled antibody therapy was approved: 
the 90Y-labeled murine antibody ibritumomab (Zevalin®), directed against the CD20 
epitope on B-cell lymphoma cells, induced significantly more complete and partial 
remissions than the unlabeled variant of the antibody in advanced and recurrent 
lymphomas. Clinical trials to treat lymphoma patients with 90Y-ibritumomab as first line 
treatment are ongoing. 
In contrast to the successful therapeutic application of radiolabeled monoclonal 
antibodies in malignant lymphoma, clinical studies in patients with solid tumors have 
shown less promising results. Several factors can be identified. First, lymphoma is a very 
radiosensitive disease as compared to the large majority of solid tumors. Second, most 
trials have been performed in patients with end-stage and bulky disease. Third, the 
therapeutic window (i.e. tumor targeting in relation to the uptake in normal organs) is 
relatively small due to the long half life in the circulation and the relatively low uptake of 
the radiolabeled antibody in the tumors. This results in significant bone marrow toxicity 
even when tumor doses are still modest. To improve the therapeutic efficacy of 
radiolabeled antibodies, several strategies have been developed, such as the use of high-
affinity ‘second generation’ antibodies, locoregional administration, treatment of patients 
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with minimal residual disease, and  treatment at maximal tolerated dose or above (in 
combination with bone marrow support). 
In ovarian cancer, the disease is limited to the peritoneal cavity in most patients. 
Theoretically, intraperitoneal administration of radiolabeled anti-tumor antibodies could 
thus lead to optimal treatment results. This is exemplified by our preclinical study in mice 
which showed a preference for i.p. administration of 90Y-HMFG1 when compared to i.v. 
administration. However, in a recent diagnostic study in which ovarian carcinoma patients 
were simultaneously injected i.v and i.p. with a radioiodinated antibody, no clear 
preference for i.p. administration was found. The efficacy of i.p. therapy with 90Y-labeled 
murine anti-MUC1 antibody (90Y-HMFG1) in patients with no evidence of disease after 
surgical debulking and chemotherapy is currently studied in a phase III study. Among 
others, inclusion criteria for this study are a negative abdominal CT-scan, no residual 
disease at a laparoscopy and a normal tumor marker CA-125. Despite this negative work-
up, eligible patients still have a relapse rate of 50 to 60% when no further treatment is 
given, being the standard of care at present due to the lack of effective adjuvant 
therapeutic options. The final results of this study are expected in the year 2004. When 
this study demonstrates a survival benefit in the active treatment arm of the study as 
compared to the standard of care (no further treatment), several questions remain: 
Is the therapeutic efficacy due to irradiation of the tumor cells or does the humoral 
response against the murine HMFG1 antibody contribute? 
Nearly all patients treated with radiolabeled murine HMFG1 develop a human anti-mouse 
antibody (HAMA) response. Several studies with radiolabeled antibodies have suggested 
that HAMA response is associated with improved survival. According to Jerne’s antibody-
network theory, anti-idiotypic humoral response to murine antibodies could give rise to 
the generation of a cascade of human anti-tumor antibodies (anti-Id2, anti-Id4, etc.). To 
elucidate the role of the humoral response, a careful analysis of the humoral response 
against HMFG1 antibody is needed. 
Could the 90Y-labeled HMFG1 antibody also be effective in patients with minimal residual 
disease? 
In the current phase III study, patient inclusion requires a negative diagnostic laparoscopy 
as the ultimate inclusion criterium. However, in clinical practice, a diagnostic laparoscopy 
at this stage is not routinely performed, since it currently does not contribute to improved 
patient management. Furthermore, laparoscopy is an invasive procedure that could have 
serious physical and mental impact on these extensively treated patients. Therefore, 
treatment without the need for a diagnostic laparoscopy would be preferable. However, 
an estimated 10 to 25 % of patients have a positive laparoscopy while abdominal CT and 
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tumor marker CA125 are within normal limits. Thus, the contribution of i.p. RIT with 90Y-
HMFG1 in patients with minimal residual disease or small volume disease as 
demonstrated by positive abdominal CT or CA125 should be studied. 
Could the use of other (more suitable) β-emitting radionuclides improve the therapeutic 
efficacy of  HMFG1-based RIT? 
The relatively long range of the β-emissions of 90Y are suboptimal for the eradication of 
cell clusters and single cells in the peritoneal cavity. Radionuclides with lower energy β-
radiation (e.g. 131I, 177Lu and 186Re) theoretically are more effective in this setting. 
However, our studies in nude mice with i.p. ovarian carcinoma did not show a clear 
benefit of the use of these medium-energy β-emitters. In patients with residual disease 
and a negative abdominal CT, the abdomen will include malignant cells ranging from 
single cells to small tumor deposits. Combined administration of low and high energy β-
emitters could possibly be suited in this clinical setting. When applied in a xenograft 
mouse model, treatment with a combination of 90Y and 177Lu-labeled somatostatin 
analogues demonstrated superior results compared to treatment with somatostatin 
labeled with either one of the radionuclides. This concept has not been tested yet in 
human RIT.          
Is RIT with 90Y-HMFG1 also effective in patients with other (i.p.) MUC-1 positive tumors? 
MUC-1 is expressed on a wide range of human adenocarcinomas. Recently, a phase I/II 
study in which patients with gastric cancer are treated with intraperitoneally administered 
90Y-HMFG1 was initiated. 
 
 
Radiolabeled peptides 
 
Radiolabeled peptides have emerged as a new class of imaging and therapeutic agents 
in nuclear medicine. Peptides are relatively small chains of amino acids that may act as a 
hormone or as a neurotransmitter in vertebrates. These peptides bind with high affinity to 
specific receptors that are expressed on the cell membrane of the target cell. For peptide 
receptor radionuclide imaging (PRRI) and peptide receptor radionuclide therapy (PRRT), 
peptides with high affinity for receptors that are preferentially expressed on tumor cells 
can be used. The best known example of such peptide is somatostatin. Somatostatin 
receptors are expressed mainly in neuroendocrine tumors. These tumors can be targeted 
with somatostatin analogs labeled with γ-emitters (111In, 99mTc, 67Ga) for imaging and with 
β-emitters (90Y, 177Lu, 188Re) for therapy. Other examples of such peptides are 
cholecystokinin (CCK)  targeting CCK-receptors on human medullary thyroid and small cell 
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lung cancer cells and bombesin targeting bombesin receptors on human lung, prostate 
and breast cancer cells.  
 
For in vivo tumor targeting the use of radiolabeled peptides has several potential 
advantages when compared to the use of radiolabeled antibodies: the small peptides will 
penetrate the tumor tissue more rapidly, peptides are non-immunogenic, enabling 
repeated administration without fast clearence by immune complex formation, and 
peptides rapidly clear from the blood thereby reducing the radiation dose to 
radiosensitive non target tissues such as the red bone marrow. 
 
Integrins play an important role in cell-cell interaction. The integrin αvβ3 is preferentially 
expressed in proliferating endothelial cells and on various tumor cells. Extracellular matrix 
proteins (vitronectin, fibronectin, laminin, a.o.) bind to αvβ3 via their RGD-sequences. 
Therefore, it was hypothesized that RGD-peptides could be used for tumor targeting. The 
potential of RGD-peptides for tumor targeting was investigated in this thesis. Our studies in 
mice with OVCAR-3 xenografts showed that cyclic RGD-peptides can selectively guide 
radionuclides to tumors. Moreover, when labeled with high activity doses of 90Y the peptide 
significantly inhibited tumor growth in this nude mouse model. 
 
As described above, myelotoxicity is dose limiting in RIT. Due to the rapid blood clearance 
of peptides, in most cases nephrotoxicity will be dose limiting in PRRT: labeled with a 
radiometal like 90Y or 177Lu, relatively high uptake of the radiolabel is observed in the 
kidneys. 
The mechanism of the high retention of the radiolabel in the kidneys following i.v. 
administration of radiolabeled peptides is relatively well understood. In general, peptides 
with a molecular weight lower than 60 kDa are filtered by the glomeruli. Under 
physiological conditions, peptides are reabsorbed by the tubular cells in the proximal 
renal tubule almost quantitatively via receptor mediated endocytosis. Upon 
internalization, the labeled peptides are degraded in the lysosomes and the metabolites 
(amino acids) are transferred back into the bloodstream. However, the metabolites of 
radiolabeled peptides (radiolabeled DTPA or DOTA-conjugated amino acids) cannot leave 
the lysosomes and will remain trapped in the proximal tubular cells. 
The radiation dose that can be guided safely to the kidneys during radionuclide therapy is 
unknown and remains to be established. From external beam irradiations of patients, it is 
known that relatively high doses (> 25 Gy) may lead to acute radiation nephropathy with a 
latency period of 6 to 12 months, while at lower doses chronic radiation nephropathy may 
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occur. Chronic renal failure generally becomes clinically apparent (uremia, edema, 
anemia, proteinuria and hypertension) between one and five years after irradiation. The 
primary site of radiation damage in the kidney is still a matter of debate. Radiation 
nephritis is associated with microangiopathy and it has been postulated that the radiation 
injury is mediated through vascular injury. On the other hand, experimental studies have 
shown that the initial stages of the process are characterized by progressive glomerular 
and tubular injury, suggesting that vascular damage might be a late complicating factor. 
In therapeutic radionuclide studies, the safe radiation dose to the kidneys of 20-25 Gy, 
derived from external beam irradiation, has been used as the maximum acceptable 
kidney dose. However, it is clear that a radiation dose delivered during radionuclide 
therapy differs in many aspects from a radiation dose delivered by external beam 
irradiation. In radionuclide therapy, the dose rate is much lower, the penetration range of 
the radiation is shorter and the radionuclide is almost exclusively localized in the tubular 
cells, while in external beam therapy the radiation is delivered homogeneously 
throughout the kidneys. Indeed, the treshold dose that induces deterministic effects in 
the thyroid due to radionuclide therapy with 131I (10 Gy) is five times higher than the 
treshold dose of external beam irradiation (2 Gy). 
There is a great need to accurately predict the radiation dose to the kidneys during PRRT. 
For this, PRRT is often preceeded by injection of the same peptide labeled with a 
diagnostic activity dose. Based on dosimetric analysis of this scout dose, the maximal 
therapeutic dose is calculated to assure that the radiation dose to the kidneys will not 
exceed 20-25 Gy. 90Y is a pure β-emitter and the kidney uptake of 90Y-labeled peptide can 
not be imaged scintigraphically. 111In is often used as a surrogate for 90Y to visualize the 
biodistribution of the 90Y-labeled peptide. However, the nature of the radionuclide may 
affect the binding affinity of the peptide for its receptor. Therefore, PET imaging using 86Y-
labeled peptides can be applied to predict the radiation dose of 90Y-labeled peptides to 
the kidneys and other organs more adequately. In dogs, we conducted a dosimetric study 
in which the dynamic distribution of 86Y and 111In-labeled RGD-peptide were compared. 
This analysis showed that doses to relevant organs as estimated from both agents were 
not significantly different, indicating that 111In-labeled RGD-peptide is a suitable  
surrogate for the 90Y-labeled RGD-peptide. Such comparison needs to be done for new 
90Y-labeled compounds before accepting the 111In-labeled compound as an adequate 
surrogate. 
Apart from the kidneys, OVCAR-3 ovarian carcinoma tumor tissue showed the highest 
uptake of the radiolabeled RGD-peptide of all organs analyzed. However, non-tumor 
organs such as intestine, liver and spleen had considerable receptor mediated RGD-
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peptide uptake. This finding was also seen in other studies with cyclic RGD-peptides. This 
suggests either the presence of αvβ3 integrin in these organs or cross reactivity of RGD-
peptides with other (integrin) receptors in these organs. It is unknown to which cell type in 
the non-tumor organs the RGD-peptide binds (vascular cells or stromal cells such as liver 
cells or splenic cells). Detailed autoradiographic studies possibly could answer this 
important question. It is known that the αvβ3 integrin is expressed on osteoclasts, vascular 
smooth muscle cells, endothelial cells and various tumor cells.  Degree of expression is 
greatly induced in remodeling or growing tissues. Biodistribution studies are generally 
carried out in young mice with tumor xenografts. It would be interesting to perform 
biodistribution studies in adult animals to measure the uptake in non-tumor tissues in these 
animals. In our studies in mice, a relatively low uptake was seen in lung and muscle tissue. 
In rats, αvβ3 integrin was found on lung vascular endothelium and not on alveolar 
endothelium. In conclusion, further studies need to emphasize the exact localization of RGD-
peptide targeting, not only in tumor tissues but also non-tumor tissues. This information is of 
great importance to understand the uptake of RGD-peptides in non-tumor tissues. 
 
As with radiolabeled antibodies, new β-emitting radionuclides could contribute to 
improved therapeutic results in PRRT. Selection of the radionuclide mainly depends on 
used labeling technique, availability and cost of the radionuclide and tumor 
characteristics (type, place, size). The relatively fast clearence of the small sized peptides 
makes radionuclides with relatively short half-lives preferable for PRRT. 177Lu could be 
more ideal than 131I and 90Y. Because many factors contributing to the therapeutic result 
are not known in detail, let alone their interactions, comparative studies are necessary to 
make a good choice between these radionuclides. 
 
To a large extent, peptides can be designed and modeled by chemical engineering. Large 
series of RGD-peptide analogues, varying by just one amino acid, have been tested in 
integrin binding assays to select the best performing sequence. In addition, both 
monomeric and dimeric RGD-peptides have been constructed. Hydrophobicity and 
hydrophylicity can be adjusted by linking certain side groups, e.g. glycosylation of amino 
acids has been applied to increase hydrophilicity of the agent to assure renal clearance. 
In our comparative monomer-dimer study, no differences in tumor uptake were 
measured. The concept of using dimers is simultaneous binding to two receptors, ideally 
leading to enhanced tumor retention. It is well possible that the spacer length between 
the RGD-rings we used was not suited to achieve this goal. Currently we are constructing 
and testing dimeric RGD-peptides with increasing spacer lenghts. 
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Conclusion 
 
Radiolabeled antibodies and peptides that selectively target malignant tumors are 
progressing from preclinical evaluation to registered products for clinical use. Most 
prominent examples are 90Y-ibritumomab and 177Lu-Tyr3-octreotate, respectively. Further 
research is necessary to answer remaining questions and to overcome issues associated 
with these therapeutic approaches. New insights and new technological progress are 
widely available to proceed with the development of better therapeutic options for 
patients with malignant diseases. 
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Chapter 8 
Summary 
 
In this thesis, preclinical studies on new treatment modalities for ovarian cancer are 
descibed, applying radiolabeled antibodies and radiolabeled RGD-peptides. 
Ovarian cancer is known as the silent lady killer: peritoneal carcinomatosis is often 
already present at first diagnosis and despite debulking surgery and chemotherapy the 
prognosis of these patients is still unfavourable (5-year survival of 20-30%). Obviously, 
there is a high need for more effective treatment. 
The use of radiolabeled antibodies for the treatment of cancer is a relatively new 
approach. With the registration of the first labeled antibody for the treatment of cancer 
(Zevalin), it has become a therapeutic option for treatment of malignant lymphoma in a 
clinical setting. The use of highly specific antibodies for antigens on lymphoma cells 
(CD20, CD22) labeled with modern and potent β-emitting radionuclides (e.g. 90Y) resulted 
in high response rates in patients with refractory and relapsed non-Hodgkin’s lymphomas. 
However, the effectiveness of radioimmunotherapy (RIT) in patients with solid tumors is 
still disappointing. Locoregional administration (e.g. intraperitoneal administration in case 
of ovarian carcinoma) and the use of more potent radionuclides could improve the 
therapeutic effect of RIT in patients with solid tumors. 
Radiolabeled peptides have emerged as a new class of therapeutic agents in nuclear 
medicine. Peptides are small chains of amino acids that may act as a hormone or as a 
neurotransmitter. These peptides bind with high affinity to specific receptors that are 
expressed on the cell membrane of the target cell. In peptide receptor radionuclide 
therapy (PRRT), peptides with high affinity for receptors that are preferentially expressed 
on tumor cells are used. The group of RGD-peptides (mostly cyclic penta-peptides in 
which the amino acid sequence Arginine-Glycine-Aspartic acid is present) is an example 
of such peptides: these peptides preferentially bind to the αvβ3 integrin, a membrane 
bound protein that connects the cytoskeleton with  extracellular matrixproteins, e.g. 
vitronectin. The αvβ3 integrin is expressed on sprouting endothelial cells and on several 
types of tumor cells. Targeting of the αvβ3 integrin with radiolabeled RGD-peptides could 
thus potentially be used to visualize and/or treat various tumor types such as ovarian 
cancer. 
In chapter 2 a study is described comparing the therapeutic efficacy of the antibody 
HMFG1 radiolabeled with several β-emitting radionuclides in mice with intraperitoneal 
(i.p.) ovarian carcinoma. Ten days after tumor inoculation, the mice were i.p. injected with 
the active radiopharmaceuticals 90Y-HMFG1, 186Re-HMFG1 or 131I-HMFG1 or the control 
agents 90Y-labeled irrelevant antibody, non-radiolabeled HMFG1 or PBS. An additional 
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group was treated with intravenously (i.v.) injected 90Y-HMFG1. Each of the i.p. 
administered radiolabeled antibody preparations caused a significant delay in tumor 
growth when compared to the control groups. No preference for either radiolabel was 
observed. Furthermore, i.p. administered 90Y-HMFG1 lead to a better survival compared 
to i.v. administered 90Y-HMFG1. These observations suggest that the choice for the 
optimal radionuclide in radioimmunotherapy depends on other factors than  the 
characteristics of the radionuclide. Apparently, the route of administration is an important 
variable in RIT: for i.p. located micrometastatic cancers such as ovarian cancer, i.p. 
administration most likely is the optimal route of administration. 
In chapter 3, initial biodistribution and therapy studies of the dimeric RGD-peptide DOTA-
E-[c(RGDfK)]2 in an ovarian cancer xenograft model are described. The peptide was 
labeled with 111In for biodistribution studies and with 90Y for therapy studies. The uptake 
in the subcutaneous xenograft peaked at 2 h postinjection. Tumor uptake was specific 
since reduced uptake in the tumor was observed after injection of an excess of non-
radioactive 115In-DOTA-E-[c(RGDfK)]2 and after injection of the scrambled control peptide 
111In-DOTA-E-[c(RGKfD)]2. At the maximal tolerated dose (37 MBq/mouse), a single i.v. 
injection of 90Y-DOTA-E-[c(RGDfK)]2 caused a significant growth delay of the ovarian 
cancer xenografts when compared to therapy with the 90Y-labeled scrambled peptide. 
This approach could further be optimized by multiple injection strategies or by using more 
potent radionuclides. 
In chapter 4 dosimetric studies of radiolabeled DOTA-E-[c(RGDfK)]2 in dogs are described. 
A dosimetrical analysis of 90Y-DOTA-E-[c(RGKfD)]2, the intended radionuclide for future 
therapy studies, cannot be performed as β-radiation cannot be visualized properly after 
injection. Therefore a substitute for 90Y should be used. Our study investigated the 
feasibility of using the readily available 111In instead of the cyclotron-produced, scarcely 
available 86Y, the latter serving as the ideal imaging surrogate for 90Y. Being a positron-
emitter, 86Y requires positron emitting tomography (PET) for imaging. 
The dogs were injected with both 111In and 86Y-labeled DOTA-E-[c(RGKfD)]2 with a time 
window of 2 weeks. A regions-of-interest analysis of the uptake in relevant organs in a set 
of 4 sequential whole-body images allowed calculation of radiation doses to these organs 
using the MIRDOSE3 computer program. To allow estimation of the radiation dose to the 
bone marrow, blood pharmacokinetics were monitored. The dose estimates to all relevant 
organs (kidney, bladder, liver, spleen and bone marrow) were similar for both (111In and 
86Y) radiolabeled RGD-peptides. Only the dose to the lungs was higher for the 111In-
labeled peptide as compared to the 86Y-labeled peptide, which could very well be caused 
by differences in the attenuation correction algorithm. It was concluded that in future 
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dosimetrical studies with these RGD-peptides, analysis of the images after injection of the 
111In-labeled peptide allows adequate estimation of the radiation doses to the relevant 
tissues. 
In chapter 5 the tumor targeting characteristics of a monomeric and a dimeric RGD-
peptide are described. Both peptides were radiolabeled with 99mTc via the 
hydrazinonicotinamide (HYNIC) moiety to form 99mTc-HYNIC-c(RGDfK) and 99mTc-HYNIC-E-
[c(RGDfK)]2, respectively. In vitro, the dimer had a 10-fold higher affinity for the αvβ3 
integrin compared to the monomer. This was confirmed in vivo in an OVCAR-3 ovarian 
carcinoma xenograft model, as the dimer showed a significantly higher uptake at 1, 2 and 
4 h postinjection. Only at the first time point analyzed (0.5 h post injection), the tumor 
uptake of both peptides was similar. Kidney retention was higher for the dimeric peptide 
than for the monomeric peptide while uptake in all other organs analyzed was equal. 
Tumor-to-kidney ratios were in favour of the monomer which is important since high 
kidney retention is unfavourable in PRRT as the kidney is the dose limiting organ. 
In chapter 6 the effect of dose fractionation on tumor targeting with a RGD-peptide was 
investigated. PRRT at the maximal tolerated dose (MTD) in nude mice of 37 MBq requires 
5 µg RGD-peptide. If 5 µg peptide would saturate the tumor and lead to lower tumor 
uptake and thus lower therapeutic efficacy, dose fractionation could improve therapeutic 
results. Therefore the protein dose was varied to circumvent saturation of the αvβ3 
integrin targets with the RGD-peptides in OVCAR-3 ovarian carcinoma xenografts. In a 
biodistribution experiment using 111In-DOTA-E-[c(RGDfK)]2, the optimal tumor uptake was 
achieved at a peptide dose of 1 µg (4.8 %ID/g). At a peptide dose of 5 µg, tumor uptake 
was reduced to 50% of the optimal uptake. After dose fractionation (5 times 1 µg; time 
interval between injections of 1 h), the fifth and last dose still had a tumor uptake of 3.3 
%ID/g. These findings lead to a study in which the therapeutic efficacy of a single 
injection of 37 MBq 90Y-DOTA-E-[c(RGDfK)]2 (peptide dose: 5 µg) was compared with 5 
injections of 7.4 MBq 90Y-DOTA-E-[c(RGDfK)]2 (peptide dose: 5 times 1 µg). The two 
approaches did not result in differences in therapeutic effect between the fractionated 
and the non-fractionated therapy. It was concluded that although 1 h after injection of 
RGD-peptides new binding sites on the αvβ3 integrin became available, therapeutic 
efficacy was not significantly improved by dose fractionation. 
In chapter 7, the results and conclusions of the studies that have been described in this 
thesis are discussed. The potential and the limitations of radiolabeled antibodies and 
RGD-peptides to use as anti-cancer agents, encountered in these studies, are 
considered. Future prospects for further studies to optimize the therapeutic efficacy of 
radiolabeled RGD-peptides are indicated. 
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Samenvatting 
 
In dit proefschrift worden preklinische studies beschreven die twee nieuwe 
therapiemogelijkheden voor het ovariumcarcinoom (eierstokkanker) onderzoeken: 
radioactief gelabelde antilichamen en radioactief gelabelde peptiden. 
Eierstokkanker staat bekend als “the silent lady killer”: bij de diagnose van de ziekte is 
vaak reeds uitgebreide peritoneale metastasering aanwezig die lange tijd geen klachten 
gegeven heeft. Ondanks debulking van de tumormassa en daaropvolgende 
chemotherapie is de prognose van deze patiënten nog steeds slecht (5-jaars overleving 
van 20-30 %). Daarom is er grote behoefte aan nieuwe, betere therapieën. 
Het gebruik van radioactief gelabelde antilichamen als behandeling van kanker is relatief 
nieuw. Recent is het eerste therapeutische radiofarmacon (Zevalin) geregistreerd als 
behandelingsmogelijkheid van het maligne lymfoom. Toediening van enkele hoog-
specifieke antilichamen, gelabeld met een krachtige β-stralers zoals 90Y en gericht tegen 
antigenen op lymfoom cellen (CD20, CD22), leidde tot hoge respons percentages bij 
patiënten met therapie-resistente vormen van Non-Hodgkin lymfoom en bij patiënten met 
recidieven van deze ziekte. De effectiviteit van radioimmunotherapie (RIT) bij patiënten 
met solide tumoren daarentegen is tot dusver teleurstellend. Nieuwe ontwikkelingen 
zoals locoregionale (bijv. intraperitoneale (i.p.)) toedieningsroutes en moderne, krachtige 
radionucliden bieden hoop op betere therapieresultaten. 
Radioactief gelabelde peptiden staan sinds enige tijd binnen de nucleaire geneeskunde 
in de belangstelling als mogelijke therapie van maligniteiten. Peptiden zijn kleine ketens 
aminozuren die in het lichaam als hormoon of intercellulaire signaaltransmitter fungeren. 
Bepaalde peptiden binden met hoge affiniteit aan specifieke membraangebonden 
receptoren die voorkomen op maligne cellen van verschillende origine. De zogenaamde 
RGD-peptiden (meest cyclische penta-peptides waarin de aminozuur sequentie arginine-
glycine-asparginezuur (RGD) aanwezig is) binden aan het integrine αvβ3, een 
membraangebonden eiwit dat een verbinding vormt tussen het cytoskelet en 
extracellulaire matrixproteïnes zoals  vitronectine. Het αvβ3 integrine komt tot 
overexpressie op jong, delend endotheel en op tumorcellen van verschillend origine 
waaronder het ovariumcarcinoom. Radioactief gelabelde RGD-peptiden zijn daarmee een 
potentieel middel voor beeldvorming en therapie van maligniteiten waaronder het 
ovariumcarcinoom. 
Hoofdstuk 2 beschrijft een studie naar de therapeutische effectiviteit van het met 
verschillende radionucliden gelabeld antilichaam HMFG1 in muizen met intraperitoneaal 
aanwezig ovariumcarcinoom. Tien dagen na inoculatie van humane ovariumtumorcellen 
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in de buikholte werden de actieve radioimmunotherapeutica (90Y-HMFG1, 186Re-HMFG1, 
131I-HMFG1) en de controles (90Y-gelabeld irrelevant antilichaam, niet gelabeld HMFG1 en 
PBS) i.p. in de muizen geïnjecteerd. Verder werd een groep behandeld met intraveneus 
(i.v.) geïnjecteerd 90Y-HMFG1. Het bleek dat behandeling met elk van de drie met een β-
straler gelabeld HMFG1 resulteerde in een significante sterfte-reductie ten opzichte van 
de drie controlegroepen. Verder liet de groep behandeld met i.p. toegediend 90Y-HMFG1 
een betere overleving zien dan de groep behandeld met i.v. toegediend 90Y-HMFG1. Deze 
resultaten suggereren dat de effectiviteit van RIT afhankelijk is van andere factoren dan 
de stralingseigenschappen van het gebruikte radionuclide. Ook de toedieningsroute is 
waarschijnlijk van belang: bij i.p. gelokaliseerde maligniteiten bestaande uit 
micrometastases zoals vaak gezien wordt bij het ovariumcarcinoom is i.p. toediening 
hoogstwaarschijnlijk de beste toedieningsroute. 
Hoofdstuk 3 beschrijft initiële biodistributie- en therapie-studies met het dimere RGD-
peptide DOTA-E-[c(RGDfK)]2 in een subcutaan ovariumcarcinoom muizenmodel. Het RGD-
peptide werd gelabeld met 111In voor de biodistributie-studies en met 90Y voor de 
therapie-studies. De maximale opname van het RGD-peptide in de tumor werd 2 uur na 
i.v. injectie bereikt. Receptorafhankelijkheid van deze opname werd aangetoond door 
zowel een sterk verminderde opname in de tumor van het controlepeptide 111In-DOTA-E-
[c(RGKfD)]2 als door een sterk verminderde opname van het radioactieve RGD-peptide 
tijdens simultane injectie van een overmaat niet-radioactief 115In-DOTA-E-[c(RGDfK)]2. 
Behandeling van de subcutane tumoren door middel van een eenmalige injectie van 90Y-
gelabeld RGD-peptide op de maximaal tolereerbare dosis (MTD) van 37 MBq leidde tot 
een significante groeivertraging van de tumoren in vergelijking met behandeling met een 
zelfde dosis van het 90Y-gelabelde controlepeptide. Verdere verbetering van de therapie 
zou mogelijk kunnen zijn door het toedienen van meerdere injecties met het gelabelde 
RGD-peptide of door het gebruik van een ander therapeutisch radionuclide. 
In hoofdstuk 4 wordt een dosimetrische studie van het RGD-peptide DOTA-E-[c(RGKfD)]2 
in honden beschreven. Dosimetrische analyse van dit RGD-peptide met de pure β-straler 
90Y, het beoogde  radionuclide voor toekomstige therapieën, is niet mogelijk omdat β-
straling na injectie niet betrouwbaar kwantificeerbaar is. Daarom dient een ander 
radionuclide gekozen te worden. De positron-emitter 86Y is hiervoor in theorie ideaal. Dit 
nuclide is echter moeilijk verkrijgbaar. Bovendien maakt 86Y het gebruik van PET-
scanning noodzakelijk. De hypothese van deze studie was dat het gemakkelijk te 
scannen en relatief goedkope 111In een goede vervanger voor 86Y is. Honden kregen een 
i.v. injectie met 111In-gelabeld RGD-peptide en twee weken later met 86Y-gelabeld RGD-
peptide. Op 4 tijdstippen werden van het hele lichaam opnamen gemaakt met een 
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gamma-camera respectievelijk een PET-camera, waarna handmatig relevante organen 
werden afgegrensd en software-matig de relatieve activiteit in deze organen werd 
bepaald. Deze data werden ingevoerd in het dosimetrie-analyseprogramma MIRDOSE3 
zodat schattingen van de stralingsdoses op de relevante organen werden verkregen. De 
stralingsdosis op het beenmerg werd ook afgeleid uit de farmacokinetiek van het RGD-
peptide in het bloed. 
De geschatte stralingsdosis op alle relevante organen was vergelijkbaar voor de beide 
RGD-peptiden met uitzondering van de dosis op de longen. De geschatte dosis op de 
longen bleek hoger voor het 111In-gelabeld peptide vergeleken met het 86Y-gelabelde 
peptide. De reden hiervoor kan gelegen zijn in het gebruikte algoritme voor de 
verzwakkingcorrectie. De conclusie van deze studie was dat in verdere dosimetrische 
analyses van het RGD-peptide het 90Y veilig vervangen kan worden door 111In in plaats 
van 86Y. 
Hoofdstuk 5 beschrijft een vergelijkende biodistributie-studie van het RGD-peptide in 
monomere en dimere vorm. Beide peptiden werden via de chelator 
hydrazinonicotinamide (HYNIC) gelabeld met 99mTc tot respectievelijk 99mTc-HYNIC-
c(RGDfK) en 99mTc-HYNIC-E-[c(RGDfK)]2. In in-vitro bindingsstudies had het dimere 
peptide een 10 maal hogere affiniteit tot het αvβ3 integrine dan het monomere peptide. 
De resultaten van de biodistributie-studie waren hiermee in lijn: in subcutane 
ovariumcarcinoom tumoren was de opname van de dimeer significant hoger op 1, 2 en 4 
uur na de injectie. Een half uur na de injectie was de opname in de tumoren voor beide 
peptiden vergelijkbaar. Opvallend was dat de nierretentie van het dimere RGD-peptide 
hoger was vergeleken met de nierretentie van het monomere RGD-peptide, terwijl de 
opname in de overige onderzochte organen vergelijkbaar was voor beide peptiden. De 
tumor-nier ratio was gunstiger voor het monomere RGD-peptide. Hoge retentie in de 
nieren is ongunstig voor beoogde therapie van tumoren met RGD-peptiden, omdat de 
nieren hierin veelal het dosislimiterende orgaan zijn. Wij concludeerden dat verdere 
studies nodig zijn om de optimale configuratie van het RGD-peptide te vinden, leidend tot 
een hoge tumoropname en een lage nierretentie. In hoofdstuk 6 werd de dosis van het 
RGD-peptide gevarieerd om de dosis vast te stellen waarbij verzadiging van OVCAR-3 
subcutane ovariumcarcinoom tumoren in muizen optreedt. Injectie van de in een eerdere 
studie vastgestelde MTD van 37 MBq 90Y-DOTA-E-[c(RGKfD)]2 betekent, op basis van de 
specifieke activiteit van het preparaat, injectie van 5 µg RGD-peptide. Als 5 µg peptide de 
tumor zou verzadigen en zou leiden tot een lagere tumor uptake, dan zou het 
gefractioneerd toedienen van de therapie het resultaat kunnen verbeteren. In een 
biodistributie-studie met 111In-DOTA-E-[c(RGDfK)]2 in naakte muizen met subcutane 
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OVCAR-3 tumoren werd de hoogste tumoropname gevonden bij een peptidedosis van 1,0 
µg (4,8 %ID/g). Bij een peptide dosis van 5 µg was de opname minder dan de helft (2,1 
%ID/g). Na fractionering van de peptide dosis (5 maal 1 µg; tijd tussen injecties 1 uur) 
bedroeg de tumor-opname 2 uur na de 5de gift 3,3 %ID/g. Dit resultaat leidde tot het 
uitvoeren van een therapie-experiment waarin de effectiviteit van een eenmalige injectie 
van 37 MBq 90Y-DOTA-E-[c(RGDfK)]2 (peptide dosis 5 µg) en 5 injecties van elk 7.4 MBq 
90Y-DOTA-E-[c(RGDfK)]2 (peptide dosis 5 maal 1 µg) vergeleken werd. Het resultaat was 
dat de groeisnelheid van de tumoren niet onderling verschilde tussen de twee 
doseringsregimes. Wij concludeerden dat hoewel reeds 1 uur na injectie van RGD-
peptiden nieuwe bindingsplaatsen op het αvβ3 integrine beschikbaar lijken te komen, de 
therapeutische effectiviteit niet significant verhoogd werd door de dosis te fractioneren. 
In hoofdstuk 7 worden de resultaten en conclusies van de beschreven studies 
bediscussieerd. De mogelijkheden en beperkingen van het gebruik van radioactief 
gelabelde antilichamen en RGD-peptiden als oncologische therapie zoals die in de 
studies naar voren kwamen worden beschouwd. Als laatste worden aanwijzingen 
gegeven voor verder onderzoek om de therapeutische effectiviteit van radioactief 
gelabelde RGD-peptiden te optimaliseren. 
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